

CHEMISTRY OF *closo*-DODECABORATE ANION $[B_{12}H_{12}]^{2-}$: A REVIEWIgor B. SIVAEV^{a1,b,*}, Vladimir I. BREGADZE^{a2} and Stefan SJÖBERG^b^a A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilov Str. 28, 119991 Moscow, Russia; e-mail: ¹ sivaev@ineos.ac.ru, ² bre@ineos.ac.ru^b Department of Organic Chemistry, Institute of Chemistry, Uppsala University, P.O. Box 531, S-751 21 Uppsala, Sweden; e-mail: ssj@kemi.uu.se

Received February 28, 2002

Accepted May 17, 2002

We have the pleasure to dedicate this paper to Jaromír Plešek on the occasion of his 75th birthday in recognition of his outstanding contribution to cage-boron chemistry.

1. Introduction	679
2. Synthesis and Properties of the $[B_{12}H_{12}]^{2-}$ Anion	680
3. Derivatives with Boron–Halogen Bond	685
4. Derivatives with Boron–Carbon Bond	687
5. Derivatives with Boron–Nitrogen Bond	693
6. Derivatives with Boron–Phosphorus and Boron–Arsenic Bonds	697
7. Derivatives with Boron–Oxygen Bond	698
8. Derivatives with Boron–Sulfur Bond	703
9. Derivatives with Boron–Selenium Bond	713
10. Metallo Derivatives	714
11. Potential Applications of <i>closo</i> -Dodecaborate Derivatives	714
12. References	717

Synthesis and chemical properties of the *closo*-dodecaborate anion $[B_{12}H_{12}]^{2-}$ and its derivatives are reviewed. Attention is also paid to potential applications of the *closo*-dodecaborate derivatives with emphasis on medical applications. A review with 325 references.

Keywords: *closo*-Dodecaborate; Synthesis; Derivatives; Applications.

1. INTRODUCTION

After the discovery of the first boranes by Alfred Stock in 1912, these compounds were considered for several decades as very exotic and to be of only academic interest¹. The boom in borane chemistry started at the end of 1940's when some of them, namely pentaborane B_5H_9 and decaborane $B_{10}H_{14}$, were believed to be most powerful rocket fuels superior to the avail-

able hydrocarbon fuels. More than 100 million dollars in the United States (Project ZIP), along with a similar number of millions of rubles in the Soviet Union, were invested in the research and development of these materials. Although this idea was abandoned later, the synthesis of these boranes on sizable scale was worked on and great efforts of many groups of chemists created a firm basis and gave a mighty impulse for the future development of borane chemistry. The real brain break in understanding borane chemistry was the concept of three-center two-electron bonding proposed by Lipscomb^{2,3} followed by the classification of the main types of deltahedra, which are the key structure units in polyhedral boron structures, by Williams^{4,5}. As a result, fifty years of intensive investigations of boranes and their derivatives have shown that this class of compounds is extremely rich and the capacity of boron to form self-bonded complex molecular networks is as extensive as of any element in the nature except for carbon.

2. SYNTHESIS AND PROPERTIES OF THE $[\text{B}_{12}\text{H}_{12}]^{2-}$ ANION

Among many thousands of known boron hydride compounds, one of central places belongs to the dodecahydro-*closo*-dodecaborate anion $[\text{B}_{12}\text{H}_{12}]^{2-}$. It has a structure of a regular icosahedron and looks as incarnation of the highest simplicity and the highest symmetry (Fig. 1). Its chemistry is not such amazing as the chemistry of metallaboranes and metallacarboranes, but it is impossible to imagine borane chemistry without this species. The history of the dodecahydro-*closo*-dodecaborate anion started in 1955 when Longuet-Higgins and Roberts⁶ on the basis of MO-LCAO calculations predicted that icosahedral borane would be stable only as dianion $[\text{B}_{12}\text{H}_{12}]^{2-}$.





FIG. 1
Structure and numbering of atoms in the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion

This prediction was verified experimentally by Hawthorne and Pitochelli in 1960 when the *closo*-dodecaborate anion was prepared for the first time as a side-product of the reaction of 2-iodododecaborane and triethylamine in refluxing benzene⁷. The isolated yield of $[B_{12}H_{12}]^{2-}$ in this reaction was less than 4%. However a few years later several high-yield methods of synthesis of the $[B_{12}H_{12}]^{2-}$ anion were proposed by different research groups⁸⁻¹².


At present there are numerous preparative methods for the synthesis of the $[B_{12}H_{12}]^{2-}$ anion. The first group of the methods includes reactions of various boranes with $H_3B \cdot L$ complexes (L is Lewis base, usually NEt_3). Triethylammonium *closo*-dodecaborate is the reaction product. The reactions of triethylamine-borane with diborane at 180 °C^{8,9} and that of triethylamine-borane with pentaborane B_5H_9 at 125 °C⁹ both produce the $[B_{12}H_{12}]^{2-}$ anion in 90% yield. The reaction of the coupled pentaborane dimer 1:2'- $[B_5H_8]_2$ with triethylamine-borane in decane at 100 °C produces the $[B_{12}H_{12}]^{2-}$ anion in 59% yield¹³. Availability of pentaborane makes these reaction sequencies attractive routes.

However, reactions employing decaborane(14) seems to be more convenient, especially in laboratory practice. One of the most convenient methods of synthesis of the *closo*-dodecaborate anion is pyrolysis of triethylamine-borane with decaborane(14) in ultrasene at 190 °C giving the desired product in 92% yield^{9,10,14} (Scheme 1).



SCHEME 1

The second group of the methods consists in interaction of alkali metal tetrahydroborates with boranes or $H_3B \cdot L$ complexes. The reaction of $NaBH_4$ with diborane at 180 °C in the presence of triethylamine gives the *closo*-dodecaborate anion in 80% yield^{8,9}. Another convenient and widely used in laboratory practice method of synthesis the $[B_{12}H_{12}]^{2-}$ anion is the reaction of sodium tetrahydroborate with decaborane in refluxing diglyme giving the target product in 91% yield^{11,15,16} (Scheme 2).



SCHEME 2

The reactions of $NaBH_4$ or KBH_4 with trimethyl- and triethylamine-borane in high-boiling alkanes (dodecane, hexadecane) at 200–250 °C result in the *closo*-dodecaborate anion in up to 95% yield and give the possibility to avoid highly toxic decaborane as starting material¹⁷⁻¹⁹. Note

however that this approach was described very briefly and did not find wide application.

Another group of methods of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion synthesis includes pyrolytic transformations of various boron hydrides. Pyrolysis of $(\text{Et}_4\text{N})\text{BH}_4$ gives a mixture of $(\text{Et}_4\text{N})_2[\text{B}_{10}\text{H}_{10}]$ and $(\text{Et}_4\text{N})_2[\text{B}_{12}\text{H}_{12}]$ as well as some $(\text{Et}_4\text{N})_2[\text{B}_9\text{H}_9]$ and $(\text{Et}_4\text{N})[\text{B}_{11}\text{H}_{14}]$. The product ratio depends strongly on the pyrolysis temperature. The formation of $(\text{Et}_4\text{N})_2[\text{B}_{10}\text{H}_{10}]$ was predominant at $185\text{ }^\circ\text{C}$ ^{20,21}. However, when the pyrolysis was performed in the presence of triethylamine-borane, the *closo*-dodecaborate anion was the main product²². Pure $(\text{Et}_4\text{N})_2[\text{B}_{12}\text{H}_{12}]$ can be obtained by chromatographic separation of a $(\text{Et}_4\text{N})_2[\text{B}_{10}\text{H}_{10}]$ - $(\text{Et}_4\text{N})_2[\text{B}_{12}\text{H}_{12}]$ mixture²³ or by reacting this mixture with triethylamine-borane²².

The study of pyrolysis of various octahydrotriborates revealed that the direction of the reaction and the yield of *closo*-borate anions depend strongly on the nature of the cation, the temperature, and the solvent used. The synthesis of the *closo*-dodecaborate anion by pyrolysis of $\text{Na}[\text{B}_3\text{H}_8]$ was proposed for the first time in early of 1960's¹², and improved later giving the desired product in the yield up to 90%^{24,25}. Pyrolysis of $\text{K}[\text{B}_3\text{H}_8]$ at $185\text{ }^\circ\text{C}$ gave a mixture of the $[\text{B}_{10}\text{H}_{10}]^{2-}$ and $[\text{B}_{12}\text{H}_{12}]^{2-}$ anions as well as some $[\text{B}_{11}\text{H}_{14}]^{-20}$, whereas increasing the temperature above $200\text{ }^\circ\text{C}$ leads mainly to $[\text{B}_9\text{H}_9]^{2-}$ and $[\text{B}_{12}\text{H}_{12}]^{2-}$ ²⁶. Pyrolysis of $\text{Rb}[\text{B}_3\text{H}_8]$ above $200\text{ }^\circ\text{C}$ gave a mixture of the $[\text{B}_9\text{H}_9]^{2-}$, $[\text{B}_{10}\text{H}_{10}]^{2-}$, and $[\text{B}_{12}\text{H}_{12}]^{2-}$ anions²⁶. Pyrolysis of $\text{Cs}[\text{B}_3\text{H}_8]$ at $185\text{ }^\circ\text{C}$ gave mainly $[\text{B}_{10}\text{H}_{10}]^{2-}$ and $[\text{B}_{11}\text{H}_{14}]^{-20}$, whereas at $230\text{ }^\circ\text{C}$ $[\text{B}_9\text{H}_9]^{2-}$, $[\text{B}_{10}\text{H}_{10}]^{2-}$, and $[\text{B}_{12}\text{H}_{12}]^{2-}$ formed²⁶. Thermal decomposition of magnesium, calcium, and strontium octahydrotriborates produce the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion in reasonable yields²⁷. Pyrolysis of tetraalkylammonium octahydroborates $(\text{R}_4\text{N})[\text{B}_3\text{H}_8]$ ($\text{R} = \text{Me}_4\text{N}, \text{Et}_4\text{N}, \text{Pr}_4\text{N}, \text{Bu}_4\text{N}$) gives $[\text{B}_{12}\text{H}_{12}]^{2-}$ as the sole product only in the case of $\text{R} = \text{Pr}$, whereas with $\text{R} = \text{Et}$, two major components are $[\text{B}_9\text{H}_9]^{2-}$ and $[\text{B}_{10}\text{H}_{10}]^{2-}$ ^{20,28}. Recently reported²⁹ an unprecedented formation of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion in the treatment of the octahydrotriborate complex $(\text{Bu}_4\text{N})[\text{W}(\text{B}_3\text{H}_8)\text{Br}(\equiv\text{CC}_6\text{H}_3\text{Me}_2)(\text{CO})_2]$ with butyllithium at $-78\text{ }^\circ\text{C}$ also should be mentioned here despite it is not pyrolytic process. It should be noted that this group of the methods require pre-synthesis of the octahydrotriborate anion, and the yield of the goal product, especially in the solid state pyrolytic processes, depends strongly on design of the apparatus used.

Thermal decomposition of the 1,4-diazabicyclo[2.2.2]octane- 2BH_3 complex in inert atmosphere at $350\text{--}450\text{ }^\circ\text{C}$ was shown to result in the formation of the corresponding *closo*-dodecaborate salt³⁰, however this process can not be considered as preparative method.

A few attempts to realize synthesis of the $[B_{12}H_{12}]^{2-}$ anion starting from other than boron hydride reagents were described. The reaction of solid NaH with a BCl_3-H_2 mixture at 250–350 °C was found to give $NaBH_4$ and $Na_2[B_{12}H_{12}]$; however, the reaction produced also considerable amounts of undesirable chloro derivatives $Na_2[B_{12}H_{12-n}Cl_n]$ ($n = 1-6$) as side products. Using $NaBH_4$ instead of NaH, the *closo*-borate yield can be increased up to 80%, but the chloro derivatives are always present in the product³¹.

Another approach consists in the use of widely available boron raw materials, such as boric acid and sodium borates in combination with various reducing agents³². More recently a solid-state synthesis of the *closo*-dodecaborate anion from potassium tetrafluoroborate and calcium hydride was proposed³³. Further development of this approach can give the *closo*-dodecaborate anion in large amount at reasonable price and open the door for its practical application.

It should be noted that the formation of the *closo*-dodecaborate anion, which is the most stable among the polyhedral boron hydrides, always takes place in the course of synthesis of other anions of the $[B_nH_n]^{2-}$ series, such as the *closo*-hexaborate $[B_6H_6]^{2-}$ ³⁴⁻³⁶ and the *closo*-nonaborate $[B_9H_9]^{2-}$ ²⁶ anions. In the case of the $[B_6H_6]^{2-}$ anion, $[B_{12}H_{12}]^{2-}$ is present in amounts exceeding the amount of the desired product and can be easily recovered^{35,36}. Similarly, the *closo*-dodecaborate anion can be prepared by the cage-expansion reactions of other *closo*-borates such as $[B_{10}H_{10}]^{2-}$ ²² and $[B_{11}H_{11}]^{2-}$ ³⁷ with triethylamine-borane.

At present, a number of salts of the *closo*-dodecaborate anion with various metal cations (lithium^{15,16}, sodium^{15,16,38,39}, potassium^{15,16,38}, rubidium^{15,16}, cesium^{15,16,38-40}, beryllium⁴¹, magnesium^{41,42}, calcium⁴¹⁻⁴³, strontium⁴¹⁻⁴³, barium^{38,41-43}, cadmium⁴¹, zinc⁴¹, aluminum³⁸, scandium⁴⁴, yttrium⁴⁴, rare earth metals^{38,44}, zirconium⁴⁵, hafnium⁴⁵, uranium⁴⁶, copper(I)^{38,47}, silver(I)⁴⁸, thallium(I)^{38,49}) and ammonium cations (NH_4^+ ⁵⁰, $Me_2NH_2^+$ ⁵⁰, Me_3NH^+ ⁵¹, Me_4N^+ ^{38,50}, $Et_2NH_2^+$ ⁵⁰, Et_3NH^+ ^{38,51}, Et_4N^+ ⁵⁰, $Bu_2NH_2^+$ ⁵⁰, Bu_3NH^+ ⁵¹, Bu_4N^+ ⁵⁰, hexyl₄ N^+ ³⁸, (2-Py)₂ NH_2^+ ⁵², $H_2NNH_3^+$ ⁵³, H_2en^{2+} ⁵⁴, $HN(C_2H_4)_3NH_2^{2+}$ ³⁰, Hbipy⁺⁵⁵), as well as the trimethylsulfonium³⁸, tetraphenylphosphonium⁵⁶, and guanidinium⁴⁷ salts have been described.

The solubility in the $M_2[B_{12}H_{12}]-MCl-H_2O$ ($M = K, Cs, Rb$)⁵⁷, $K_2[B_{12}H_{12}]-KBr-H_2O$ ⁵⁸, $Cs_2[B_{12}H_{12}]-CsI-H_2O$ ⁵⁹, $Cs_2[B_{12}H_{12}]-CsNO_3-H_2O$ ⁶⁰, and $Cs_2[B_{12}H_{12}]-Cs_2SO_4-H_2O$ ⁶¹ systems at 25 °C have been investigated. It was found that alkali metal *closo*-dodecaborates form mixed salts with the corresponding halides, $M_2[B_{12}H_{12}].MX$ ($M = K, X = Br, I$; $M = Rb, X = Cl, Br, I$; $M = Cs, X = Cl, Br, I$)^{38,62-64}. It was shown that the formation of the mixed salts is determined by the sum of the ionic diameters of the metal

and halogen, which should be more than 6.46 \AA ⁶⁴. In addition to the mixed salts of *closo*-dodecaborates of alkali metals and thallium with the corresponding nitrates $M_2[B_{12}H_{12}]\cdot MNO_3$ ($M = Rb, Cs, Tl$) and tetrahydroborates $M_2[B_{12}H_{12}]\cdot MBH_4$ ($M = K, Rb, Cs, Tl$), were prepared^{49,65,66}. Synthesis of the 1 : 2 complexes of $(R_4N)_2[B_{12}H_{12}]$ ($R = Me, Et, Bu$) with $Al(BH_4)_3$ was also described⁶⁷.

In addition, the syntheses of a number of compounds of the *closo*-dodecaborate anion with complex nickel^{38,53,68–77}, cobalt^{38,69–74,78}, iron^{69,79–88}, chromium³⁸, manganese⁷⁰, platinum⁶⁹, palladium^{69,89}, ruthenium⁹⁰, lead^{53,91–93}, copper^{70,94–95}, mercury⁷⁰, cadmium⁷⁰, zinc⁷⁰, rare earth metals^{96–104}, and uranium^{105–109} cations have been described. The $[B_{12}H_{12}]^{2-}$ anion ranks among weakly coordinating anions^{110,111} and serves as an outer-sphere anion in the absolute majority of these complexes. The rare examples where the *closo*-dodecaborate anion acts as inner-sphere ligand are $Me_4N[CuB_{12}H_{12}]$ ^{94,95} and $[(PhMe_2P)_3RuB_{12}H_{12}]$ ⁹⁰. Another example of coordination of $[B_{12}H_{12}]^{2-}$ to the metal atoms is its complex with cyclic trimeric tetrafluoro-1,2-phenylenemercury $(Bu_4N)_2\{[(1,2-C_6F_4Hg)_3]_2[B_{12}H_{12}]\}$, where the *closo*-dodecaborate anion is coordinated to all six mercury atoms of two molecules of the Lewis acid¹¹² (Fig. 2). It was shown that the weakly




FIG. 2

Crystal structure of $(Bu_4N)_2\{[(1,2-C_6F_4Hg)_3]_2[B_{12}H_{12}]\}$

coordinating ability of the *closo*-dodecaborate anion can be used to prepare salts with labile double-charged cations¹¹³.

The crystal structures of $\text{Na}_2[\text{B}_{12}\text{H}_{12}]\cdot 4\text{H}_2\text{O}$ ^{114,115}, $\text{K}_2[\text{B}_{12}\text{H}_{12}]$ ¹¹⁶, $\text{Rb}_2[\text{B}_{12}\text{H}_{12}]$ ¹¹⁷, $\text{Cs}_2[\text{B}_{12}\text{H}_{12}]$ ¹¹⁸, $[\text{Ca}(\text{H}_2\text{O})_7][\text{B}_{12}\text{H}_{12}]$ ^{119,120}, $[\text{Sr}(\text{H}_2\text{O})_7][\text{B}_{12}\text{H}_{12}]$ ¹²¹, $[\text{Sr}(\text{H}_2\text{O})_8][\text{B}_{12}\text{H}_{12}]$ ¹²⁰, $[\text{Ba}(\text{H}_2\text{O})_6][\text{B}_{12}\text{H}_{12}]$ ^{120,122}, $[\text{UO}_2(\text{H}_2\text{O})_5][\text{B}_{12}\text{H}_{12}]\cdot 6\text{H}_2\text{O}$ ¹²³, $(\text{Me}_3\text{NH})_2[\text{B}_{12}\text{H}_{12}]\cdot 2\text{DMF}$ ¹²⁴, $(\text{Me}_4\text{N})_2[\text{B}_{12}\text{H}_{12}]$ ¹²⁵, $(\text{Me}_4\text{N})_2[\text{B}_{12}\text{H}_{12}]\cdot \text{MeCN}$ ¹²⁵, $(\text{Et}_3\text{NH})_2[\text{B}_{12}\text{H}_{12}]$ ¹²⁶, $(\text{Bu}_4\text{N})_2[\text{B}_{12}\text{H}_{12}]$ ²⁹, $\text{K}_2[\text{B}_{12}\text{H}_{12}]\cdot \text{KBr}$ ⁶⁴, $[\text{Ni}(\text{en})_3][\text{B}_{12}\text{H}_{12}]$ ¹²⁷, $(\eta^5\text{-C}_5\text{H}_4\text{CH}_2\text{NHMe}_2)_2[\text{B}_{12}\text{H}_{12}]$ ¹²⁹, $(\eta^5\text{-C}_5\text{H}_5)\text{Fe}(\eta^6\text{-C}_6\text{H}_4\text{-1,2-(CH}_2)_4)_2[\text{B}_{12}\text{H}_{12}]$ ¹³⁰, $(\eta^5\text{-C}_5\text{H}_5)\text{Fe}(\eta^6\text{-C}_6\text{H}_5\text{CH(CH}_3)_2)_2[\text{B}_{12}\text{H}_{12}]$ ¹³¹, $[\text{Pb}(\text{bipy})_2][\text{B}_{12}\text{H}_{12}]$ ⁹¹, $[\text{Pb}(\text{bipy})\text{-(DMF)}][\text{B}_{12}\text{H}_{12}]$ ⁹², $(\text{DIME})\text{Yb}(\text{CH}_3\text{CN})_5[\text{B}_{12}\text{H}_{12}]$ ⁹⁶, and $(\text{Bu}_4\text{N})_2\{[(1,2\text{-C}_6\text{F}_4\text{Hg})_3]_2\text{-}[\text{B}_{12}\text{H}_{12}]\}$ ¹¹² have been determined by the single-crystal X-ray diffraction method.

The $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion is stable to heating in strong aqueous sodium hydroxide and 3 M hydrochloric acid at 95 °C. The acid form $(\text{H}_3\text{O})_2[\text{B}_{12}\text{H}_{12}]\cdot x\text{H}_2\text{O}$ displays properties of a strong acid which is comparable in strength with sulfuric acid. The *closo*-dodecaborate salts with thermally stable cations have also high thermal stability. For example, $\text{Cs}_2[\text{B}_{12}\text{H}_{12}]$ does not change under heating at 810 °C³⁸. The electrochemical study of $(\text{Et}_4\text{N})_2[\text{B}_{12}\text{H}_{12}]$ in acetonitrile revealed that the *closo*-dodecaborate anion undergoes one-electron oxidation at $E_{1/2} = + 1.50$ V (vs SCE) giving anion $[\text{B}_{24}\text{H}_{23}]^{3-}$ as the product¹³². The high stability of the *closo*-dodecaborate anion can be explained by the three-dimensional aromatic character of the bonding in the B_{12} cage^{133,134}.

3. DERIVATIVES WITH BORON-HALOGEN BOND

In accordance with its aromatic character, the chemistry of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion features mainly aromatic substitution reactions. Halogenations of the *closo*-dodecaborate anion were studied repeatedly by several research groups. Fluorination of the *closo*-dodecaborate anion with hydrogen fluoride gives derivatives with different substitution degrees $[\text{B}_{12}\text{H}_{12-x}\text{F}_x]^{2-}$, $x = 1\text{--}12$ ¹³⁵⁻¹⁴². The substitution degree depends on the molar ratio of the reagents and the reaction temperature. The structures of the fluoro derivatives prepared were determined by NMR spectroscopy and X-ray diffraction analysis and the substitution sequence was established. It was shown that a fluorine atom acts as deactivating *meta*-directing substituent. A nucleophilic aromatic substitution mechanism was proposed for the fluorination in liquid hydrogen fluoride¹³⁹, however more probably that this reaction proceeds *via* electrophile-induced nucleophilic substitution mechanism. The experimental data were found to be in good agreement with the results

of the semiempirical MNDO calculations of the different isomers of $[B_{12}H_{12-x}F_x]^{2-}$ ¹³⁹. The monofluoro derivative $[B_{12}H_{11}F]^{2-}$ was also prepared by heating $K_2[B_{12}H_{12}]$ in KHF_2 melt at 290 °C¹⁴¹ and by reaction of $Cs_2[B_{12}H_{12}]$ with 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) at room temperature in aqueous dimethylformamide^{143a}. The perfluoro derivative can be prepared easily by treatment of solution of $[1,2,8,10-B_{12}H_8F_4]^{2-}$ in liquid hydrogen fluoride with fluorine gas at room temperature^{143b}. The crystal structures of $K_2[1,7-B_{12}H_{10}F_2] \cdot H_2O$, $Cs_2[1,2,4,5,8,9,11-B_{12}H_5F_7] \cdot H_2O$, $Cs_2[1,2,4,5,7,8,9,11-B_{12}H_4F_8] \cdot 2H_2O$, $0.4K_2[B_{12}H_4F_8] \cdot 0.6K_2[B_{12}H_3F_9] \cdot 2H_2O$, and $Cs_2[B_{12}F_{12}] \cdot H_2O$ were determined^{139,141,144}.

The monochloro derivative $[B_{12}H_{11}Cl]^{2-}$ can be prepared by the reaction of $(H_3O)_2[B_{12}H_{12}] \cdot nH_2O$ with anhydrous hydrogen chloride at 85 °C¹³⁵ as well as by the reaction of the tetrabutylammonium salt with dichloromethane in the presence of trifluoroacetic acid¹⁴⁵, or by the treatment of the sodium salt in water with $H[AuCl_4]$ ¹³⁵. Chlorination of $[B_{12}H_{12}]^{2-}$ with chlorine in water gives a mixture of $[B_{12}H_{11}Cl]^{2-}$, $[1,2-B_{12}H_{10}Cl_2]^{2-}$, $[1,7-B_{12}H_{10}Cl_2]^{2-}$, $[1,2,3-B_{12}H_9Cl_3]^{2-}$, and $[1,7,9-B_{12}H_9Cl_3]^{2-}$ derivatives^{146,147}, which can be separated by chromatography on 2-hydroxyethyl methacrylate gels¹⁴⁸. The reaction of $(H_3O)_2[B_{12}H_{12}] \cdot nH_2O$ with chlorine in water at 0 °C gives $[B_{12}H_6Cl_6]^{2-}$ ¹³⁵. The perchloro derivative $[B_{12}Cl_{12}]^{2-}$ has been prepared by the treatment of $[B_{12}H_{12}]^{2-}$ with chlorine at 85 °C in acidic aqueous solution^{149,150} or at 150 °C in water^{135,151}. The crystal structure of $[1,1'-CH_2(C_5H_5N)_2][B_{12}H_{11}Cl] \cdot 2(CH_3)_2SO$ was determined¹⁴⁵.

The monobromo derivative $[B_{12}H_{11}Br]^{2-}$ was prepared by the reaction of $[B_{12}H_{12}]^{2-}$ with dibromomethane in the presence of trifluoroacetic acid¹⁴⁵. Treatment of $[B_{12}H_{12}]^{2-}$ with bromine in a water-tetrachloromethane mixture gave a mixture of $[B_{12}H_{11}Br]^{2-}$, $[1,2-B_{12}H_{10}Br_2]^{2-}$, and $[1,7-B_{12}H_{10}Br_2]^{2-}$ derivatives^{146,147}, which can be separated by chromatography on 2-hydroxyethyl methacrylate gels¹⁴⁸. The reaction of $[B_{12}H_{12}]^{2-}$ with bromine in aqueous methanol at -10 °C was shown to give a mixture of tetra- and pentabromo derivatives¹⁵², whereas the same reaction at 5 °C gives the hexabromo derivative $[B_{12}H_6Br_6]^{2-}$ ¹³⁵. Heating $(H_3O)_2[B_{12}H_{12}] \cdot nH_2O$ with bromine in water at 80–90 °C results in the decabromo derivative $[B_{12}H_2Br_{10}]^{2-}$ ¹³⁵. The perbromo derivative $[B_{12}Br_{12}]^{2-}$ was prepared by the treatment of $[B_{12}H_6Br_6]^{2-}$ with bromine in the presence of chlorine in 50% aqueous methanol^{135,151}. The crystal structure of $[1,1'-CH_2(C_5H_5N)_2][B_{12}H_{11}Br]$ was determined¹⁴⁵.

The monoiodo derivative $[B_{12}H_{11}I]^{2-}$ was prepared by the reaction of $[B_{12}H_{12}]^{2-}$ with 1 equivalent of iodine in aqueous methanol at 0 °C¹³⁵ and by the reaction with diiodomethane in the presence of trifluoroacetic acid¹⁴⁵. The use of 2 equivalents of iodine results in the disubstituted product which is mainly 1,7-isomer¹³⁵. The periodo derivative $[B_{12}I_{12}]^{2-}$ was prepared by refluxing $Na_2[B_{12}H_{12}]$ with iodine monochloride in 1,1,2,2-tetrachloroethane or nonyl alcohol^{135,151}. The crystal structures of $[1,1'-CH_2(C_5H_5N)_2][B_{12}H_{11}I]$ ¹⁴⁵ and $Cs_2[B_{12}I_{12}] \cdot 2MeCN$ ¹⁵³ were determined.


Acid properties of the perhalogenated *closo*-dodecaborate acids $(H_3O)_2[B_{12}X_{12}] \cdot nH_2O$ (X = Cl, Br, I) were investigated and was shown that like $(H_3O)_2[B_{12}H_{12}] \cdot nH_2O$ they are strong acids^{151,154-156}.

A series of mixed halogen derivatives of the *closo*-dodecaborate anion have been prepared by straightforward combinations of the halogenation reactions¹³⁵ and photoinduced nucleophilic substitution in perhalogenated *closo*-dodecaborates¹⁵².

A number of complexes of halogenated *closo*-dodecaborates with various metals have been synthesized^{68,105,106,113,157-161}. In all the cases halogenated *closo*-dodecaborates serve as outer-sphere anions.


4. DERIVATIVES WITH BORON-CARBON BOND

At present a large number of derivatives of the $[B_{12}H_{12}]^{2-}$ anion with boron-carbon bond were described. Probably, the most interesting of the *closo*-dodecaborate derivatives with boron-carbon bond are carbonyl derivatives. The reaction of the $[B_{12}H_{12}]^{2-}$ acid with carbon monoxide at 1 000 atm and 130 °C in the presence of $[Co_2(CO)_8]$ as a catalyst gives almost a quantitative conversion to a mixture of mono- and disubstituted carbonyl derivatives, $[B_{12}H_{11}CO]^-$ (50%), $[1,12-B_{12}H_{10}(CO)_2]$ (40%), and $[1,7-B_{12}H_{10}(CO)_2]$ ^{162,163}. The 1,7- and 1,12-isomers can be separated by fractional crystallization from water as cesium salts of the corresponding carboxylic acid derivatives¹⁶³ (Scheme 3).



SCHEME 3

The neutral carbonyl derivatives are colorless, easily subliming hygroscopic compounds, which are highly soluble in both polar and non-polar solvents¹⁶³. In aqueous solutions, an equilibrium between the carbonyl and carboxylic forms was proposed¹⁶² (Scheme 4).



SCHEME 4

It should be noted that the predominant formation of $[1,12\text{-B}_{12}\text{H}_{10}(\text{CO})_2]$ is very rare example of *para*-substitution in the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion. It can be explained by significant redistribution of electron density in the boron cage after introduction of the first carbonyl group resulting in the most positive charge on the antipodal boron atom. This conclusion is supported by the ^{11}B NMR spectrum of $[\text{B}_{12}\text{H}_{11}\text{CO}]^-$ demonstrating uniquely large high- and low-field shifts for signals corresponding to the substituted and antipodal boron atoms, respectively¹⁷⁵.

The structure of $[1,12\text{-B}_{12}\text{H}_{10}(\text{CO})_2]$ (Fig. 3) was determined by the method of X-ray diffraction¹⁶⁴. The molecule has D_{5d} symmetry with average B–B distances: apical–equatorial 1.768 Å, equatorial–equatorial 1.824 Å, and equatorial–equatorial' 1.779 Å. The B–CO fragment is nearly linear (B–C–O 179.18°; B–C 1.543 Å, C–O 1.119 Å). It should be noted that the experimentally determined bond lengths significantly differ from those based on the MNDO calculations¹⁶⁵. The presence of the carbonyl groups considerably disturbs the charge distribution in the boron hydride system. The BH groups in $[1,12\text{-B}_{12}\text{H}_{10}(\text{CO})_2]$ have a charge equal to -0.04 (in comparison with -0.17 for $[\text{B}_{12}\text{H}_{12}]^{2-}$ ¹⁶⁶), and the charge of the BCO fragment is distributed in the following manner: B, -0.32 ; C, $+0.58$; O, -0.06 ¹⁶⁵. This results correlate well with another calculation giving an overall charge for the CO group $+0.4$ ¹⁶⁴.




FIG. 3
Molecular structure of $[1,12\text{-B}_{12}\text{H}_{10}(\text{CO})_2]$

The X-ray structure study of the hydrated acidic form $[1,12\text{-B}_{12}\text{H}_{10}(\text{CO}_2\text{H}_2)_2] \cdot 4\text{H}_2\text{O}$ revealed unexpectedly that, at least in the solid state, it exists in the carbene diol form (Fig. 4) (B–C 1.589 Å, C–O 1.288 Å, O–H 0.85 Å)¹⁶⁴. The data on the acidic properties of the hydrated form are some contradictory. The $\text{p}K_1$ and $\text{p}K_2$ values reported are 4.2 and 9.0 (preliminary data)¹⁶⁴ as well as 9.07 and 10.24¹⁶⁷. It seems, however, that this contradiction is imaginary: more probably that the 4.2 value corresponds to loss of the first two protons from the carbene diols giving $[1,12\text{-B}_{12}\text{H}_{10}(\text{COOH})_2]^{2-}$, whereas the 9.0 value corresponds to loss of the two carboxylic protons giving $[1,12\text{-B}_{12}\text{H}_{10}(\text{COO})_2]^{4-}$; the 9.07 and 10.24 values were from the beginning determined for dissociation of the first and the second protons from $[1,12\text{-B}_{12}\text{H}_{10}(\text{COOH})_2]^{2-}$ giving $[1,12\text{-B}_{12}\text{H}_{10}(\text{COOH})(\text{COO})]^{3-}$ and $[1,12\text{-B}_{12}\text{H}_{10}(\text{COO})_2]^{4-}$, respectively. It should be noted however, that actual form of the existence of the dicarboxylic derivative (dihydroxycarbene or hydroxonium salt) in solutions and especially in diluted solutions is unknown.

The decrease in the effective negative charge on the BH groups apparently explains the extremely slow rate of halogenation of the carbonyl derivatives in anhydrous media. However, halogenation of the carboxylic species readily takes place in water with the formation of the completely substituted derivatives $[\text{B}_{12}\text{Br}_{11}\text{COOH}]^{2-}$, $[1,12\text{-B}_{12}\text{Br}_{10}(\text{COOH})_2]^{2-}$, and $[1,12\text{-B}_{12}\text{I}_{10}(\text{COOH})_2]^{2-}$ ¹⁶³.

Carbonyl derivatives of the *closo*-dodecaborate anion have a high reactivity with respect to nucleophiles and can serve as starting compounds for synthesis of various derivatives of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion. Their reactions with




FIG. 4
Molecular structure of $[1,12\text{-B}_{12}\text{H}_{10}(\text{C}(\text{OH})_2)_2]$

The carbonyl function can be introduced also by the treatment with oxalyl chloride. The reaction of $[B_{12}H_{12}]^{2-}$ with oxalyl chloride in dichloromethane or acetonitrile at room temperature results in its quantitative conversion into the monocarbonyl derivative $[B_{12}H_{11}CO]^{-}$ ^{175,176}. This method gives possibility to easily prepare $[B_{12}H_{11}CO]^{-}$ in ordinary chemical laboratory and makes it a very promising synthon for preparation of various monosubstituted derivatives of the *closo*-dodecaborate anion. The reaction of $[B_{12}H_{11}NMe_3]^{-}$ with oxalyl chloride in refluxing acetonitrile gives a mixture of [1,7- and 1,12-Me₃NB₁₂H₁₀CO] in low yield¹⁷⁷.

The reduction of [1,12-B₁₂H₁₀(CO)₂] with lithium aluminium hydride in 1,2-dimethoxyethane gave the hydroxymethyl derivative $[1,12-B_{12}H_{10}-(CH_2OH)_2]^{2-}$. The latter was converted to the iodomethyl derivative $[1,12-B_{12}H_{10}(CH_2I)_2]^{2-}$ by heating in 57% hydroiodic acid at 40–50 °C. A number of anionic and neutral nucleophiles were used in turn to displace iodide from the iodomethyl derivative to make $[1,12-B_{12}H_{10}(CH_2X)_2]^{2-}$ (X = N₃, SCN) and $[1,12-B_{12}H_{10}(CH_2L)_2]$ (L = NMe₃, NHMe₂, PMe₃). The second-generation derivatives were obtained by proton abstraction from $[1,12-B_{12}H_{10}(CH_2NHMe_2)_2]$ with butyllithium, followed by the reaction with organic halides, to make $[1,12-B_{12}H_{10}(CH_2NMe_2Y)_2]$ (Y = Me, CH₂COOEt, CHMeCOOEt, COOEt)¹⁷³.

Chlorination of the hydroxymethyl derivative in acetonitrile results in its chlorination and oxidation to the chlorinated carboxylic derivative $[1,12-B_{12}Cl_{10}(COOH)_2]^{2-}$ ¹⁷³. The carboxyl groups can be cleaved from the B₁₂ cage by halogen under free-radical conditions with the formation of perhalogenated derivatives¹⁶³.

The ketone derivatives $[B_{12}H_{11}COR]^{2-}$ (R = CH₂C₆H₅, CH₂CH₂C₆H₅, C₆H₅, 1-C₁₀H₇, 4-O₂NC₆H₄, 4-ClC₆H₄, 4-BrC₆H₄) were prepared by the reaction of Na₂[B₁₂H₁₂] with the corresponding acyl chlorides in acetone. $[B_{12}H_{11}OH]^{2-}$ was the reaction by-product. The ratio of the products obtained depended on the nature of R¹⁷⁸.

The reactions of (Bu₄N)₂[B₁₂H₁₂] with iodo-, bromo-, 1,3-dibromo-, 1,3-dichloro-, 1,2-dichloro-, and 1,2,3-trichlorobenzenes at 160–180 °C resulted in the corresponding aryl derivatives $[B_{12}H_{12-n}Ar_n]^{2-}$ (n = 1–3)^{179–181}. The phenyl derivative $[B_{12}H_{11}C_6H_5]^{2-}$ was obtained by the reaction of (Bu₄N)₂[B₁₂H₁₂] with triphenyltin chloride Ph₃SnCl at 170 °C¹⁸².

The phenyl derivative was also prepared by the palladium-catalyzed coupling of (Bu₄N)₂[B₁₂H₁₁I] with PhMgBr in 1,4-dioxane¹⁸³ or with PhZnCl in tetrahydrofuran¹⁸⁴. The reaction of $[B_{12}H_{10}INH(CH_2Ph)_2]^{-}$ with 1-naphthylmagnesium bromide in refluxing tetrahydrofuran in the presence of

[PdCl₂(PPh₃)₂] and CuI gives [(PhCH₂)₂HNB₁₂H₁₀-1-C₁₀H₇]⁻¹⁸⁵. Similar reactions of with (Bu₄N)₂[B₁₂H₁₁I] with methylmagnesium bromide in 1,4-dioxane, or methylzinc chloride or octadecylmagnesium chloride in tetrahydrofuran result in the corresponding alkyl derivatives [B₁₂H₁₁R]²⁻ (R = CH₃, C₁₈H₃₇)^{183,184}. The monomethyl derivative was obtained also by the reaction of [B₁₂H₁₁I]²⁻ with refluxing trimethylaluminium¹⁸⁶.

The permethylated derivative [B₁₂Me₁₂]²⁻ was prepared by heating (Bu₄N)₂[B₁₂H₁₂] with trimethylaluminium and methyl iodide¹⁸⁶. The permethylated dianion [B₁₂Me₁₂]²⁻ can be easily oxidized with cerium(IV) ammonium nitrate to give the air-stable blue anion-radical {[B₁₂Me₁₂]^{•-}}, which can be reversibly reduced with sodium borohydride¹⁸⁷.

The structures of (Ph₄As)₂[B₁₂H₁₁Ph]¹⁸², ((Ph₃P)₂N)₂[B₁₂H₁₁Ph]·2Me₂SO·toluene¹⁸³, Cs₂[B₁₂H₁₁Me]¹⁸³, [(C₅H₅N)₂CH₂][B₁₂Me₁₂]·MeCN¹⁸⁶, and ((Ph₃P)₂N)[B₁₂Me₁₂]¹⁸⁷ were determined by X-ray diffraction.


It was reported that the [B₁₂H₁₂]²⁻ anion reacts with olefins in acid medium to form alkyl and polyalkyl derivatives^{188,189}. However, these reactions are difficult to control, and result in mixtures of derivatives with varying degree of substitution.

The reaction of (H₃O)₂[B₁₂H₁₂]·nH₂O with tropylium bromide results in the tropylium derivative [B₁₂H₁₁C₇H₆]⁻, which belongs to the class of so-called "ousenes", compounds, which offer an opportunity for charge transfer from the negatively charged boron cage to the positively charged aromatic ring¹⁹⁰⁻¹⁹². The recent molecular orbital study^{192b} revealed that the tropylium derivative has additional low lying π-orbital in which a pair of the cage electrons are completely delocalized throughout the cage and the ring that results in the extraordinary stability of this tropylium derivative.

It was reported^{152,193} that the dodecabromo-*closo*-dodecaborate anion [B₁₂Br₁₂]²⁻ undergoes nucleophilic substitution with the cyanide ion under UV irradiation in aqueous solution to give successively [B₁₂Br₃(CN)₉]²⁻, [B₁₂HBr₂(CN)₉]²⁻, and [B₁₂H₂Br(CN)₉]²⁻. Under similar conditions, [B₁₂H₂Br₁₀]²⁻ gives [B₁₂H₂Br₂(CN)₈]²⁻ and [B₁₂H₂Br(CN)₉]²⁻. The less substituted halogen derivatives do not undergo a photoinduced nucleophilic substitution. The heating of [B₁₂H₂Br(CN)₉]²⁻ and [B₁₂H₂Br₂(CN)₈]²⁻ at 200 °C in concentrated sulfuric acid results in the corresponding carboxylic derivatives. The dodecachloro-*closo*-dodecaborate anion [B₁₂Cl₁₂]²⁻ reacts with cyanide ion under UV irradiation to give [B₁₂Cl₅(CN)₇]²⁻. In principle, these derivatives could serve as precursors for synthesis of supramolecular structures, however, on our knowledge this study was never revised and stereochemistry of the polycyano derivatives are unknown.

5. DERIVATIVES WITH BORON-NITROGEN BOND

The *closo*-dodecaborate derivatives with boron-nitrogen bond attract attention of boron chemists from the 1960's when simple and effective methods for substitution of nitrogen functions for hydrogen atom were developed. One of the most important is the reaction of the *closo*-dodecaborate anion with hydroxylamine-*O*-sulfonic acid in aqueous solution giving mono- and disubstituted amino derivatives which, because of their high basicity, are readily isolated in the *N*-protonated forms. The diamino derivative was obtained as a mixture of the 1,7-, 1,12-, and a small amount of 1,2-isomers, which can be separated by fractional crystallization from water^{172,185,194} (Scheme 7).




SCHEME 7

The 1,12-isomer can also be obtained by the reaction of hydroxylamine-*O*-sulfonic acid with the dicarbonyl derivative [1,12- $\text{B}_{12}\text{H}_{10}(\text{CO})_2$]^{163,172} (Scheme 8).




SCHEME 8

Treatment of the amino derivatives with dimethyl sulfate in alkaline solution results in the corresponding trimethylamine derivatives¹⁷² (Scheme 9).



SCHEME 9

The disubstituted trimethylamine derivatives were obtained also by the reaction of $[\text{B}_{12}\text{H}_{11}\text{NMe}_3]^-$ with oxalyl chloride in refluxing acetonitrile followed by the treatment with hydroxylamine-*O*-sulfonic acid and dimethyl sulfate¹⁷⁶ (Scheme 10).





SCHEME 10

Thermal stability of the $[\text{B}_{12}\text{H}_{10}(\text{NMe}_3)_2]$ isomers was found to decrease in the order 1,12- > 1,7- > 1,2-isomer. The 1,12-isomer does not melt up to 530 °C

and fails to undergo polyhedral isomerization up to this temperature. The 1,7-isomer undergoes slight isomerization to the 1,2-isomer at 400 °C. The 1,2-isomer undergoes rapid decomposition at the melting point¹⁷⁴ (375 °C).


A series of alkylamine derivatives were prepared by deprotonation of $[B_{12}H_{11}NH_3]^-$ with strong bases (sodium hydride or potassium hydroxide) followed by the reaction with alkyl halides^{185,195,196} (Scheme 11).



SCHEME 11

The alkylation reaction gives, as a rule, a mixture of derivatives with varying substitution degrees. Using an excess of the alkylating agent results in derivatives with the maximum possible degree of substitution, which is dependent on the steric restrictions offered by the alkyl groups. This can be demonstrated by the reaction of $[B_{12}H_{11}NH_3]^-$ with ethyl iodide which gives $[B_{12}H_{11}NEt_3]^-$, whereas the reaction with benzyl chloride gives $[B_{12}H_{11}NH(CH_2Ph)_2]^-$. The use of equimolar amounts of alkylating agent usually gives mixtures of mono- and dialkylamine derivatives. The dialkylamine derivatives $[B_{12}H_{11}NHR_2]^-$ can be methylated with dimethyl sulfate or methyl iodide to give $[B_{12}H_{11}NR_2Me]^-$. The monoalkylamine derivatives could be obtained in reasonable yields only in the case of strongly sterically hindered alkylating agents, such as phthalocyanine derivatives^{197,198}.

The [(15-azacrown-5) $B_{12}H_{11}$]⁻ anion was prepared by the reaction of $[B_{12}H_{11}NH_3]^-$ with pentaethylene glycol ditosylate in the presence of sodium hydride in tetrahydrofuran¹⁸⁵ (Scheme 12).



SCHEME 12

A number of trialkylamine derivatives $[B_{12}H_{11}NR_3]^-$ were prepared by high-temperature reactions of diborane or adducts of borane with Lewis bases $BH_3 \cdot L$ (L is trimethylamine, ethyl(dimethyl)amine, diethyl(methyl)amine, *N*-methylpiperidine, cyclohexyl(dimethyl)amine)^{8,9}. The triethylamine derivative $[B_{12}H_{11}NEt_3]^-$ was obtained also in the reaction of


decaborane $B_{10}H_{14}$ with triethylamine-borane^{8,10}. The unsubstituted *closo*-dodecaborate anion is the main product in all of these reactions; however, the $[B_{12}H_{11}NEt_3]^-$ yield can be increased by up to 60% in the presence of an excess of triethylamine¹⁹⁹.

The triethylamine derivative was found to form unexpectedly in the reaction of $(Et_3NH)_2[B_{12}H_{12}]$ with $[RuCl_2(PPh_3)_3]$ in refluxing ethanol and was isolated as the $[(PPh_3)_2ClRuB_{12}H_{11}NEt_3]$ complex⁹⁰.

The crystal molecular structures of $Cs[B_{12}H_{11}NH_3] \cdot 2MeOH$ ²⁰⁰, $K[B_{12}H_{11}NEt_3]$ ¹⁹⁹, $(Me_4N)[B_{12}H_{11}NEt_3]$ ²⁰¹, $(Bu_4N)[B_{12}H_{11}NEt_3]$ ¹⁹⁶, $[(PPh_3)_2ClRuB_{12}H_{11}NEt_3]$ ⁹⁰, $(Ph_3P)_2N[B_{12}H_{11}NH_2-i-Pr]$ ¹⁹⁶, $(Ph_3P)_2N[B_{12}H_{11}NH(i-Pr)_2]$ ¹⁹⁶, $((Ph_3P)_2N)[B_{12}H_{11}NH(CH_2Ph)_2]$ ¹⁹⁶, and $[1,7-B_{12}H_{10}(NH_3)_2] \cdot 0.5H_2O$ ¹⁹⁴ were determined by X-ray diffraction.

Halogenation of amine- and alkylamine derivatives of the *closo*-dodecaborate anion under various conditions was studied^{185,202,203}. The crystal structures of $(Ph_3C)[B_{12}F_{11}NMe_3]$ and $(Bu_4N)[B_{12}F_{11}NH(CH_2C_6H_5)_2]$ were determined by X-ray diffraction²⁰³.


The (chloromethyl)dimethylamine derivatives were obtained by the reaction of the *closo*-dodecaborate anion with the Vilsmeier reagent²⁰⁴ (Scheme 13).



SCHEME 13

This reaction was re-examined recently and $[1,7-B_{12}H_{10}(NMe_2CH_2Cl)_2]$ was shown to be the main product isolated in 51% yield, whereas the monosubstituted derivative $[B_{12}H_{11}NMe_2CH_2Cl]^-$ and $[B_{12}H_{11}OH]^{2-}$ formed in lower amounts. The crystal molecular structure of $[1,7-B_{12}H_{10}(NMe_2CH_2Cl)_2]$ was determined²⁰⁵.

The reaction of $[B_{12}H_{11}NH_3]^-$ with aldehydes in methanol in the presence of catalytic amounts of alkali gives the corresponding Schiff bases $[B_{12}H_{11}NH=CHR]^-$ ²⁰⁶⁻²⁰⁸ (Scheme 14).




R = C_6H_5 , 2- $MeOC_6H_4$, 4- $MeOC_6H_4$, 4- $MeSC_6H_4$, 4- $Me_2NC_6H_4$, 4- $AcNHC_6H_4$, 4- NCC_6H_4 , 4- ClC_6H_4 , 4- BrC_6H_4 , 3,4- $CH_2O_2C_6H_3$, 1- $C_{10}H_7$, 2- $C_{10}H_7$, Me-CH=CH, Ph-CH=CH

SCHEME 14

The crystal molecular crystal structures of $(\text{Bu}_4\text{N})[\text{B}_{12}\text{H}_{11}\text{NH}=\text{CHC}_6\text{H}_4\text{-4-NMe}_2]$, CHCl_3 and $(\text{Bu}_4\text{N})[\text{B}_{12}\text{H}_{11}\text{NH}=\text{CHC}_6\text{H}_4\text{-2-OMe}]$ have been determined by single-crystal X-ray analysis. Both anions were found to have *trans*-configuration²⁰⁶.

The reduction of the Schiff bases with sodium borohydride in aqueous propan-2-ol gives the corresponding amines^{206–208} (Scheme 15).




SCHEME 15

This approach was used for the synthesis of a series of derivatives of the *closo*-dodecaborate anion with various functional groups connected to the aromatic ring $[\text{B}_{12}\text{H}_{11}\text{NH}_2\text{CH}_2\text{C}_6\text{H}_4\text{-4-X}]^-$ ($\text{X} = \text{NH}_2, \text{COOH}, \text{NCS}$)^{206–208}.


The reactions of $(\text{Bu}_4\text{N})_2[\text{B}_{12}\text{H}_{12}]$ with 4-aminopyridine and 2,2'-bipyridine at 190 °C gave $[(4\text{-pyridylNH}_2)\text{B}_{12}\text{H}_{11}]^-$ and $[1\text{-}(2,2'\text{-bipyridyl})\text{B}_{12}\text{H}_{11}]^-$, respectively. The crystal molecular structures of $(\text{Ph}_4\text{As})[(4\text{-pyridylNH}_2)\text{B}_{12}\text{H}_{11}]\cdot 2\text{MeCN}$ ²⁰⁹ and $(\text{Ph}_4\text{As})[1\text{-}(2,2'\text{-bipyridyl})\text{B}_{12}\text{H}_{11}]\cdot \text{MeCN}$ ²¹⁰ were determined by X-ray diffraction.

The alkylamide derivatives can be prepared by reaction of the amino derivative with acyl chlorides¹⁸⁵ (Scheme 16).



SCHEME 16

The acetamide, acrylamide, and cyanoacetamide derivatives were prepared by the reaction of the *closo*-dodecaborate anion with the corresponding nitriles in the presence of 4-methylbenzene-1-sulfonic acid. The nitrilium intermediate was hydrolyzed with traces of water to give the corresponding amides^{132,211–213} (Scheme 17).




SCHEME 17

The lanthanide complexes with the acetamide and acrylamide ligands $\text{Ln}[\text{B}_{12}\text{H}_{11}\text{NH}_2\text{COR}]_3\cdot 5\text{H}_2\text{O}$ ($\text{Ln} = \text{La}, \text{Pr}, \text{Nd}, \text{Sm}, \text{Eu}, \text{Gd}, \text{Ho}, \text{Er}, \text{Tm}, \text{Yb}, \text{Ln}$) were synthesized^{211–213}.

Small amounts of $[\text{B}_{12}\text{H}_{11}\text{NH}_2\text{COCH}_3]^-$, $[\text{B}_{12}\text{H}_{11}\text{NH}_2\text{COCH}_2\text{COOEt}]^-$, $[\text{B}_{12}\text{H}_{11}\text{NH}_2\text{COCH}_2\text{OSO}_2\text{Ph}]^-$, and $[\text{B}_{12}\text{H}_{10}(\text{NH}_2\text{COCH}_2\text{CONH}_2)_2]$ were isolated from the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with the appropriate nitriles (acetonitrile, ethyl cyanoacetate, cyanomethyl benzenesulfonate, malononitrile) in the presence of FeCl_3 ²¹⁴.

The isocyanate derivatives $[\text{B}_{12}\text{H}_{11}\text{NCO}]^{2-}$, [1,7- and 1,12- $\text{B}_{12}\text{H}_{10}(\text{NCO})_2]^{2-}$ were prepared by the reaction of the corresponding carbonyl derivatives with sodium azide^{163,168}. Hydrolysis of [1,12- $\text{B}_{12}\text{H}_{10}(\text{NCO})_2]^{2-}$ in acidic solution gives the diamino derivative [1,12- $\text{B}_{12}\text{H}_{10}(\text{NH}_2)_2]$, whereas the reaction with alcohol in the presence of acid results in urethane¹⁶³ (Scheme 18).




SCHEME 18

The nitroso derivative $[\text{B}_{12}\text{H}_{11}\text{NO}]^{2-}$ derivative was prepared by the treatment of the *closo*-dodecaborate with nitrous acid in aqueous solution or with isopentyl nitrite and nitrosyl chloride in noaqueous solutions²¹⁵.

Short irradiation (1.5–2 h) of the dodecabromo-*closo*-dodecaborate anion $[\text{B}_{12}\text{Br}_{12}]^{2-}$ in the presence of excess of azide ion produces $[\text{B}_{12}\text{Br}_{11}\text{N}_3]^{2-}$ and $[\text{B}_{12}\text{Br}_{10}(\text{N}_3)_2]^{2-}$ anions which could be separated by fractional crystallization¹⁵².


6. DERIVATIVES WITH BORON-PHOSPHORUS AND BORON-ARSENIC BONDS

The trimethylphosphonium derivatives of the dodecaborate anion were obtained by pyrolysis of the trimethylphosphine–borane complex, where the $[\text{B}_{12}\text{H}_{11}\text{PMe}_3]^-$ yield reaches 60%^{8,9} (Scheme 19).



SCHEME 19

The [1,7- $\text{B}_{12}\text{H}_{10}(\text{PMe}_2\text{Ph})_2]$ complex was obtained by the reaction of the *closo*-dodecaborate anion with $[\text{PdCl}_2(\text{Me}_2\text{PhP})_2]$ in tetrahydrofuran²¹⁶ (Scheme 20).



SCHEME 20

The trimethylarsonium derivatives $[\text{B}_{12}\text{H}_{11}\text{AsMe}_3]^-$ and $[\text{B}_{12}\text{H}_{10}(\text{AsMe}_3)_2]$ were obtained by pyrolysis of the trimethylarsine–borane complex^{8,9}.

7. DERIVATIVES WITH BORON-OXYGEN BOND

At present, many methods for the synthesis of the hydroxy derivative of the *closo*-dodecaborate anion $[\text{B}_{12}\text{H}_{11}\text{OH}]^{2-}$ are described in the literature. One approach includes the interaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with amides in acid media followed by alkaline hydrolysis of the formed intermediates. For example, heating the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with 1-methylpyrrolidin-2-one at 180 °C in the presence of hydrochloric acid gives the corresponding 1-methyl-1-pyrrolinio-2-yloxy derivative which can be easily hydrolyzed with alkali to $[\text{B}_{12}\text{H}_{11}\text{OH}]^{2-}$ ^{189,217}. The reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with tetramethylurea at 165 °C in the presence of concentrated sulfuric acid gives $[\text{B}_{12}\text{H}_{11}\text{OC}(\text{NMe}_2)_2]^-$ in high yield; however, its hydrolysis has not been reported²⁰². The other method consists in the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with sulfones under acid conditions. The reactions with tetrahydrothiophene 1,1-dioxide or dipropyl sulfone gave the corresponding derivatives, $[\text{B}_{12}\text{H}_{11}\text{OS}(\text{O})\text{C}_4\text{H}_8]^-$ or $[\text{B}_{12}\text{H}_{11}\text{OS}(\text{O})\text{Pr}_2]^-$. Alkaline hydrolysis of the first one was reported to result in the hydroxy derivative²⁰².

The hydroxy derivative was also prepared by refluxing the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion in acidic propan-2-ol followed by hydrolysis of the formed isopropoxy derivative with concentrated hydrobromic acid¹⁸⁹. The hydroxy derivative can be prepared also by the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with acetyl chloride in acetone²¹⁸, by the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ acid with sulfur dioxide at 60 °C under pressure¹⁸⁹, or by mild oxidation of the *closo*-dodecaborate anion with oxalic acid^{189,219}. The syntheses of the hydroxy derivative $[\text{B}_{12}\text{H}_{11}\text{OH}]^{2-}$ by the reaction of the *closo*-dodecaborate with aqueous sulfuric acid at 90 °C^{220,221} or with refluxing acetic acid followed by alkaline hydrolysis of the acetoxy intermediate²²² have been described quite recently. It should be mentioned that only the methods based on the alkaline hydrolysis of the pyrrolidinium intermediate²¹⁷ or the acetoxy²²² derivative, and the hydroxylation of the *closo*-dodecaborate with sulfuric acid²²⁰ give high yields (to 75–80%) and can be used as preparative methods.

The perchloro derivative $[\text{B}_{12}\text{Cl}_{11}\text{OH}]^{2-}$ was prepared by chlorination of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with gaseous chlorine in aqueous solution at 90 °C¹⁸⁹. The perbromo analogue $[\text{B}_{12}\text{Br}_{11}\text{OH}]^{2-}$ was prepared by bromination of $[\text{B}_{12}\text{H}_{11}\text{O-i-Pr}]^{2-}$ with bromine in water¹⁸⁹.

The dihydroxy derivative $[\text{B}_{12}\text{H}_{10}(\text{OH})_2]^{2-}$ was obtained as a mixture of the 1,2- and 1,7-isomers by heating $[\text{B}_{12}\text{H}_{12}]^{2-}$ in a mixture of acetone and concentrated hydrochloric acid at 80 °C²¹⁵. The pure $[1,2\text{-B}_{12}\text{H}_{10}(\text{OH})_2]^{2-}$ isomer was obtained by alkaline hydrolysis of $[1,2\text{-C}_6\text{H}_5\text{CH}_2\text{C}(\text{O})\text{-OB}_{12}\text{H}_{10}\text{OH}]^{2-}$ ²²³. The pure $[1,7\text{-B}_{12}\text{H}_{10}(\text{OH})_2]^{2-}$ isomer was prepared by the

reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with 1-methylpyrrolidin-2-one at 205–250 °C in the presence of hydrochloric acid followed by alkaline hydrolysis of the intermediate formed^{171,189,220} or by the reaction of $(\text{H}_3\text{O})_2[\text{B}_{12}\text{H}_{12}] \cdot n\text{H}_2\text{O}$ with ethylene glycol at 160 °C²²⁴ and by the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with aqueous sulfuric acid at 90 °C²²¹. The bromination of $[\text{1,7-B}_{12}\text{H}_{10}(\text{OH})_2]^{2-}$ with bromine in aqueous solution gives the corresponding perbromo derivative $[\text{1,7-B}_{12}\text{Br}_{10}(\text{OH})_2]^{2-}$ ¹⁸⁹.


The trisubstituted hydroxy derivative $[\text{1,2,3-B}_{12}\text{H}_9(\text{OH})_3]^{2-}$ was obtained by heating of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion in a mixture of acetone and concentrated hydrochloric acid at 100 °C²¹⁸, whereas the 1,7,9-isomer was shown to form in the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with aqueous sulfuric acid at 110 °C^{220,221}.

The tetrasubstituted hydroxy derivative $[\text{1,2,8,10-B}_{12}\text{H}_8(\text{OH})_4]^{2-}$ was obtained by the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with aqueous sulfuric acid at 175 °C^{220,221}.

The perhydroxy derivative $[\text{B}_{12}(\text{OH})_{12}]^{2-}$ was prepared by heating the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with 30% hydrogen peroxide under reflux^{225,226}. The same product was also obtained from the reaction of the monocarboxylato derivative $[\text{B}_{12}\text{H}_{11}\text{COO}]^{2-}$ and hydrogen peroxide, whereas $[\text{B}_{12}\text{H}_{11}\text{C}_6\text{H}_5]^{2-}$ and $[\text{B}_{12}\text{H}_{11}\text{I}]^{2-}$ were degraded to boric acid when heated with 30% hydrogen peroxide at the reflux²²⁶.

The crystal structures of $\text{Cs}_2[\text{B}_{12}\text{H}_{11}\text{OH}] \cdot \text{AcOH}$ ²²², $(\text{Ph}_3\text{PMe})_2[\text{B}_{12}\text{H}_{11}\text{OH}]$ ²²⁰, $(\text{Ph}_4\text{P})_2[\text{B}_{12}\text{H}_{11}\text{OH}] \cdot 0.74\text{AcOH} \cdot 0.52\text{H}_2\text{O}$ ²²², $(\text{Ph}_3\text{PMe})_2[\text{1,7-B}_{12}\text{H}_{10}(\text{OH})_2]$ ²²⁰, $\text{Na}_2[\text{B}_{12}(\text{OH})_{12}] \cdot 4\text{H}_2\text{O}$ ²²⁶, $\text{K}_2[\text{B}_{12}(\text{OH})_{12}]$ ²²⁶, $\text{Rb}_2[\text{B}_{12}(\text{OH})_{12}] \cdot 2\text{H}_2\text{O}$ ²²⁶, and $\text{Cs}_2[\text{B}_{12}(\text{OH})_{12}] \cdot 2\text{H}_2\text{O}$ ^{225,226} have been established by the X-ray diffraction method.

Alkylation of $[\text{B}_{12}\text{H}_{11}\text{OH}]^{2-}$ with alkyl halides in dimethyl sulfoxide in the presence of potassium hydroxide²²⁷ or in acetone in the presence of potassium carbonate²²⁸ gives the alkoxy derivatives $[\text{B}_{12}\text{H}_{11}\text{OR}]^{2-}$ (Scheme 21).



SCHEME 21

The synthesis of a boron-containing glucoside based on the $[\text{B}_{12}\text{H}_{11}\text{OH}]^{2-}$ anion was reported²²⁹.

The alkoxy derivatives were obtained also by the reaction of the *closo*-dodecaborate anion with alcohols and ethers in acidic media. Formation of a number of such derivatives has been described in the early 1960's¹⁸⁹. Recently the ethoxy derivative $[B_{12}H_{11}OEt]^{2-}$ was shown to be formed by the treatment of the $[B_{12}H_{12}]^{2-}$ anion with hydrogen fluoride in ethanol²³⁰.


The phenoxy derivative $[B_{12}H_{11}OPh]^{2-}$ was prepared by refluxing $(Bu_4N)_2[B_{12}H_{12}]$ in anisole¹⁷⁹. Its perbromo analogue $[B_{12}Br_{11}OPh]^{2-}$ was obtained by UV irradiation of the $[B_{12}Br_{12}]^{2-}$ anion in aqueous solution of potassium phenolate¹⁵².

The 1,7-dialkoxy derivatives $[1,7-B_{12}H_{10}(OR)_2]^{2-}$ (R = Me, Et) were obtained by the reaction of $Na_2[B_{12}H_{12}]$ with dichloromethyl methyl ether in acetone followed by alcoholysis of the formed intermediate with the corresponding alcohols²³¹.

The reaction of $[B_{12}(OH)_{12}]^{2-}$ with benzyl bromide in acetonitrile in the presence of ethyl(diisopropyl)amine at the reflux temperature produces the per-*O*-benzylated derivative $[B_{12}(OCH_2C_6H_5)_{12}]^{2-}$. Salts of the $[B_{12}(OCH_2C_6H_5)_{12}]^{2-}$ anion slowly air-oxidize to give purple paramagnetic anion-radical $[B_{12}(OCH_2C_6H_5)_{12}]^{\bullet-}$. The latter can be easily obtained by one-electron oxidation of $[B_{12}(OCH_2C_6H_5)_{12}]^{2-}$ with 1 equivalent of iron(III) chloride. The sequential two-electron oxidation of $[B_{12}(OCH_2C_6H_5)_{12}]^{2-}$ with excess of $FeCl_3$ in ethanol gives dark orange *hypercloso*- $[B_{12}(OCH_2C_6H_5)_{12}]^{232}$.


The crystal structures of $Cs[(Ph_3P)_2N][B_{12}(OCH_2C_6H_5)_{12}]$, $[(Ph_3P)_2N][B_{12}(OCH_2C_6H_5)_{12}]$, and $[B_{12}(OCH_2C_6H_5)_{12}]$ have been established by the single-crystal X-ray diffraction²³².

The oxonium derivatives $[B_{12}H_{11}O(CH_2)_4]^-$ or $[B_{12}H_{11}O(CH_2CH_2)_2O]^-$ were prepared by the treatment of the parent *closo*-dodecaborate anion with $BF_3 \cdot Et_2O$ in tetrahydrofuran or 1,4-dioxane, respectively. The diethyloxonium derivative $[B_{12}H_{11}OEt_2]^-$ was obtained by the reaction of $[B_{12}H_{12}]^{2-}$ with 4-nitrobenzoyl chloride in an acetone-diethyl ether mixture²³³. The tetramethylene oxonium derivative $[B_{12}H_{11}O(CH_2)_4]^-$ undergoes the ring opening under nucleophilic attack with various nucleophiles giving a useful method for the synthesis of a series of functional derivatives of the *closo*-dodecaborate anion $[B_{12}H_{11}O(CH_2)_4X]^{2-}$ (X = OH, NH₂, COOH, CH(NH₂)COOH)^{233,234} (Scheme 22).



SCHEME 22

Using lithium derivatives of *o*-, *m*-, and *p*-carboranes as nucleophiles, the compounds containing both the *closo*-dodecaborate and the corresponding carborane cages were synthesized²³⁴ (Scheme 23).




SCHEME 23

A similar approach was used for the synthesis of neutral oxonium derivatives on the basis of dibenzylamino-*closo*-dodecaborate - $[(C_6H_5CH_2)_2HNB_{12}H_{10}O(CH_2)_4]$ and $[(C_6H_5CH_2)_2HNB_{12}H_{10}O(CH_2CH_2)_2O]$. The ring-opening reaction in these derivatives was used for preparation of extractants for purification of nuclear wastes²³⁵.

The pentamethylene oxonium derivative $[B_{12}H_{11}O(CH_2)_5]^-$ was prepared by the reaction of $[B_{12}H_{11}OH]^{2-}$ with 1,5-dibromopentane in the presence of potassium hydroxide in dimethyl sulfoxide²²⁷. This compound also undergoes the ring-opening reaction, under nucleophilic attack with fluoride or hydroxide ions, giving the corresponding alkoxy derivatives $[B_{12}H_{11}O(CH_2)_5X]^{2-}$ (X = F, OH)²³⁶.

The acyloxy derivatives $[B_{12}H_{11}OC(O)R]^{2-}$ were shown to be formed by the reaction of $(Bu_4N)_2[B_{12}H_{12}]$ with formic, acetic, cyanoacetic, phenylacetic, propionic, butyric, palmitic, and stearic acids at 90–150 °C^{223,237} (Scheme 24).




R = H, CH₃, C₂H₅, *n*-C₃H₇, *n*-C₁₅H₃₁, *n*-C₁₇H₃₅, CH₂C₆H₅, CH₂CN

SCHEME 24

The disubstituted [1,2- and 1,7-B₁₂H₁₀(OC(O)R)₂]²⁻ derivatives were by-products in the case of acetic, propionic, and butyric acids and the main products in the case of palmitic and stearic acids at 120–150 °C, whereas in the case of phenylacetic acid [1,2-C₆H₅CH₂C(O)OB₁₂H₁₀OH]²⁻ forms. A high yield (70%) was obtained only for the acetoxy derivative [B₁₂H₁₁OAc]²⁻^{223,237}.

The acyloxy derivatives were also prepared by acylation of the [B₁₂H₁₁OH]²⁻ anion with acyl chlorides in acetonitrile in the presence of a base^{217,227} (Scheme 25).



R = CH₃, C₆H₅, 4-ClC₆H₄, 4-MeOC₆H₄

SCHEME 25

In the case of acyl chlorides of dicarboxylic acids (oxalyl chloride, terephthaloyl and isophthaloyl chlorides), the corresponding bridged dicluster compounds [B₁₂H₁₁OC(O)RC(O)OB₁₂H₁₁]⁴⁻ were obtained in good yields²²⁴.

Slow addition of iodine in propan-2-ol to aqueous solution of [B₁₂H₁₁OC(O)CH₃]²⁻ results in formation of [1-CH₃C(O)O-12-I-B₁₂H₁₀]²⁻²³⁸.

Acylation of [1,2-B₁₂H₁₀(OH)₂]²⁻ with oxalyl chloride gives the cyclic oxalato derivative [1,2-μ-OC(O)C(O)O-B₁₂H₁₀]²⁻. Similarly, the reaction of [1,7-B₁₂H₁₀(OH)₂]²⁻ with sebacyl chloride produces [1,7-μ-OC(O)(CH₂)₈C(O)O-B₁₂H₁₀]²⁻²²⁴.

Acylation of [B₁₂(OH)₁₂]²⁻ with acetic anhydride or with benzoyl chloride in acetonitrile in the presence of triethylamine at reflux temperature gives the corresponding per-*O*-acylated derivatives [B₁₂(OC(O)CH₃)₁₂]²⁻ and [B₁₂(OC(O)C₆H₅)₁₂]²⁻²³⁹. This approach was used for synthesis of the dodeca-(carboranyl)-substituted anion, [B₁₂(OC(O)(CH₂)₆-1-(2-CH₃-1,2-C₂B₁₀H₁₀)₁₂]²⁻²⁴⁰.

Heating the acyloxy derivatives in 1 M NaOH at 60 °C results in complete hydrolysis to the parent hydroxy derivatives^{223,237}.

The reactions of [B₁₂H₁₁OH]²⁻ with thionyl or sulfonyl chlorides in acetonitrile in the presence of pyridine give [B₁₂H₁₁OS(O)OB₁₂H₁₁]⁴⁻ and [B₁₂H₁₁OSO₂OB₁₂H₁₁]⁴⁻, respectively²²⁴. The phosphorylation of [B₁₂H₁₁OH]²⁻ with phosphorus oxychloride in pyridine gives

$[\text{B}_{12}\text{H}_{11}\text{OPO}_3\text{H}]^{3-}$ and $[\text{B}_{12}\text{H}_{11}\text{OPO}_3\text{H}_2]^{2-}$ depending on the medium acidity. A similar reaction with $(\text{PhO})_2\text{POCl}$ results in $[\text{B}_{12}\text{H}_{11}\text{OP}(\text{O})(\text{OPh})_2]^{2-}$ and $[\text{B}_{12}\text{H}_{11}\text{OP}(\text{O})(\text{OPh})\text{OH}]^{2-}$ as products²⁴¹.

The reaction of $[1,2\text{-B}_{12}\text{H}_{10}(\text{OH})_2]^{2-}$ with sulfuryl chloride results in the formation of the cyclic sulfato $[1,2\text{-}\mu\text{-OSO}_2\text{O-B}_{12}\text{H}_{10}]^{2-}$ derivative²²⁴. The reaction of $[1,7\text{-B}_{12}\text{H}_{10}(\text{OH})_2]^{2-}$ with methanesulfonyl chloride in refluxing pyridine gives $[1,7\text{-B}_{12}\text{H}_{10}(\text{OSO}_2\text{Me})_2]^{2-}$ ²²⁰. Phosphorylation of $[1,7\text{-B}_{12}\text{H}_{10}(\text{OH})_2]^{2-}$ with phosphorus oxychloride gives $[1,7\text{-B}_{12}\text{H}_{10}(\text{OPO}_3\text{H})_2]^{4-}$, $[1,7\text{-B}_{12}\text{H}_{10}(\text{OPO}_3\text{H})(\text{OPO}_3\text{H}_2)]^{3-}$, and $[1,7\text{-B}_{12}\text{H}_{10}(\text{OPO}_3\text{H}_2)_2]^{2-}$ depending on the medium acidity²⁴¹. The bromination of the phosphate derivatives with bromine in aqueous solution produces $[1,7\text{-B}_{12}\text{Br}_{10}(\text{OPO}_3\text{H})_2]^{4-}$. The reaction of $[1,7\text{-B}_{12}\text{H}_{10}(\text{OH})_2]^{2-}$ with $(\text{PhO})_2\text{POCl}$ results in $[1,7\text{-B}_{12}\text{H}_{10}(\text{OP}(\text{O})(\text{OPh})_2)_2]^{2-}$ ²⁴¹.

The crystal molecular structures of $[1,1'\text{-CH}_2(\text{C}_5\text{H}_5\text{N})_2][\text{B}_{12}\text{H}_{11}\text{OEt}]^{231}$, $(\text{Bu}_4\text{N})_2[\text{B}_{12}\text{H}_{11}\text{OEt}]^{227}$, $\text{Cs}[(\text{Ph}_3\text{P})_2\text{N}][\text{B}_{12}(\text{OCH}_2\text{C}_6\text{H}_5)_{12}]^{232}$, $[(\text{Ph}_3\text{P})_2\text{N}][\text{B}_{12}\text{H}_{11}\text{O}(\text{CH}_2)_5]^{227}$, $(\text{Bu}_4\text{N})_2[\text{B}_{12}\text{H}_{11}\text{OC}(\text{O})\text{Me}]^{227}$, $(\text{Bu}_4\text{N})_2[\text{B}_{12}\text{H}_{11}\text{OC}(\text{O})\text{Ph}]^{227}$, $\text{Cs}_2[1,2\text{-}\mu\text{-OC}(\text{O})\text{C}(\text{O})\text{O-B}_{12}\text{H}_{10}]\cdot\text{MeOH}^{224}$, $\text{Cs}_2[\text{B}_{12}(\text{OC}(\text{O})\text{CH}_3)_{12}]\cdot 2\text{SC}(\text{NH}_2)_2^{239}$, $(\text{Ph}_4\text{P})_2[\text{B}_{12}(\text{OC}(\text{O})\text{C}_6\text{H}_5)_{12}]^{239}$, and $(\text{pyH})_2[1,7\text{-B}_{12}\text{H}_{10}(\text{OSO}_2\text{Me})_2]^{220}$ were determined by X-ray diffraction.

The reactions of $[\text{B}_{12}\text{H}_{11}\text{OH}]^{2-}$, $[1,7\text{-B}_{12}\text{H}_{10}(\text{OH})_2]^{2-}$, and $[1,7,9\text{-B}_{12}\text{H}_{10}(\text{OH})_2]^{2-}$ with titanocene dichloride Cp_2TiCl_2 in refluxing acetonitrile gave the corresponding dichloro(cyclopentadienyl)titaniumoxy derivatives $[\text{B}_{12}\text{H}_{11}\text{OTiCpCl}_2]^{2-}$, $[1,7\text{-B}_{12}\text{H}_{10}(\text{OTiCpCl}_2)_2]^{2-}$, and $[1,7,9\text{-B}_{12}\text{H}_9(\text{OTiCpCl}_2)_3]^{2-}$. The crystal structure of $(\text{Ph}_3\text{PMe})_2[\text{B}_{12}\text{H}_{11}\text{OTiCpCl}_2]$ was determined by X-ray diffraction²²⁰.


The reaction of $[\text{B}_{12}\text{H}_{11}\text{OH}]^{2-}$ with phenyl isocyanate in pyridine gives the corresponding carbamate $[\text{B}_{12}\text{H}_{11}\text{OC}(\text{O})\text{NHPh}]^{2-}$ ²²⁰. In a similar way, the reactions $[\text{B}_{12}(\text{OH})_{12}]^{2-}$ with isocyanates give the corresponding carbamates²⁴². UV irradiation of the dodecabromo-*closo*-dodecaborate anion $[\text{B}_{12}\text{Br}_{12}]^{2-}$ in aqueous solution in the presence of excess of the cyanate ion gives the cyanato derivatives, $[\text{B}_{12}\text{Br}_{11}\text{OCN}]^{2-}$ and $[\text{B}_{12}\text{Br}_{10}(\text{OCN})_2]^{2-}$, which can be easily hydrolyzed to the corresponding hydroxy derivatives¹⁵².

8. DERIVATIVES WITH BORON-SULFUR BOND

At present the chemistry of the *closo*-dodecaborate derivatives with boron-sulfur bond is the most actively studied field in the $[\text{B}_{12}\text{H}_{12}]^{2-}$ chemistry. The great interest to these compounds is caused by the use of sodium mercapto-*closo*-dodecaborate $\text{Na}_2[\text{B}_{12}\text{H}_{11}\text{SH}]$ as an agent for boron neutron capture therapy for cancer.


The mercapto derivative was obtained for the first time by the reaction of $(\text{H}_3\text{O})_2[\text{B}_{12}\text{H}_{12}] \cdot n\text{H}_2\text{O}$ with hydrogen sulfide in the early 1960's¹⁸⁹. It was shown later that the reaction gives a mixture of the mono- and dimercapto derivatives as well as the hydroxy derivatives²⁴³. However, the yield of the monomercapto derivative $[\text{B}_{12}\text{H}_{11}\text{SH}]^{2-}$ after work-up does not exceed 25%.

More convenient methods of synthesis of the mercapto derivative which are used in its routine preparation include the interaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with thiocarbonyl compounds in acid media followed by alkaline hydrolysis of the formed intermediates (Scheme 26).



SCHEME 26

An alternative method consists in the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with thiourea under conditions of electrochemical oxidation²⁴⁶ (Scheme 27).



SCHEME 27

The crystal structure of $\text{Cs}_2[\text{B}_{12}\text{H}_{11}\text{SH}] \cdot \text{H}_2\text{O}$ was determined by single-crystal X-ray diffraction²⁴⁷.


The acidic properties of the $[\text{B}_{12}\text{H}_{11}\text{SH}]^{2-}$ anion were studied and it was found that the mercapto group has an unusually high pK_a value of 13.4²⁴⁸.

A few examples of formation of complexes with participation of the $[\text{B}_{12}\text{H}_{11}\text{SH}]^{2-}$ anion were described. The reaction of $\text{Cs}_2[\text{B}_{12}\text{H}_{11}\text{SH}]$ with

$[\text{RuCl}(\text{NH}_3)_5]\text{Cl}_2$ in aqueous solution results in a dark blue complex, $[(\text{B}_{12}\text{H}_{11}\text{S})\text{Ru}(\text{NH}_3)_5]\cdot 2\text{H}_2\text{O}$, the structure of which was determined by X-ray diffraction. The $[\text{B}_{12}\text{H}_{11}\text{S}]^{3-}$ ligand is strongly nucleophilic and demonstrates a strong *trans* effect²⁴⁹.

Formation of self-assembled monolayers by spontaneous adsorption of the $[\text{B}_{12}\text{H}_{11}\text{SH}]^{2-}$ anions on gold surface from aqueous solutions of $\text{Cs}_2[\text{B}_{12}\text{H}_{11}\text{SH}]$ was shown²⁵⁰. The exchange of PPh_3 in $\text{Au}_{55}(\text{PPh}_3)_{12}\text{Cl}_6$ for $\text{Na}_2[\text{B}_{12}\text{H}_{11}\text{SH}]$ using a phase-transfer reaction from dichloromethane to water results in the very stable $\text{Na}_{24}[\text{Au}_{55}(\text{B}_{12}\text{H}_{11}\text{SH})_{12}\text{Cl}_6]$ complex²⁵¹ (Fig. 5).

Mild oxidation of $[\text{B}_{12}\text{H}_{11}\text{SH}]^{2-}$ with sodium iodosobenzoate^{243,252} or nickel peroxide^{253,254} gives the disulfide $[\text{B}_{12}\text{H}_{11}\text{SSB}_{12}\text{H}_{11}]^{4-}$ (Scheme 28).



SCHEME 28

The disulfide formation was found also as a result of the autooxidation of $[\text{B}_{12}\text{H}_{11}\text{SH}]^{2-}$ with molecular oxygen in aqueous solution^{243,254-256}.

Treatment of $[\text{B}_{12}\text{H}_{11}\text{SSB}_{12}\text{H}_{11}]^{4-}$ with iodine monochloride in tetrachloroethane results in the periodinated disulfide derivative $[\text{B}_{12}\text{I}_{11}\text{SSB}_{12}\text{I}_{11}]^{4-}$ ²⁵⁷.

Acidification of solutions of the disulfide $[\text{B}_{12}\text{H}_{11}\text{SSB}_{12}\text{H}_{11}]^{4-}$ in some organic solvents (acetone, ethanol, acetonitrile, dimethylformamide, dimethyl sulfoxide) results in formation of a deep blue stable radical. The





FIG. 5
Model of the cluster part $[\text{Au}_{55}(\text{B}_{12}\text{H}_{11}\text{SH})_{12}]^{24-}$





SCHEME 31

Acidification of a solution of $[\text{B}_{12}\text{H}_{11}\text{SSCH}_2\text{CH}_2\text{COON}(\text{CO})_2(\text{CH}_2)_2]^{2-}$ in dimethyl sulfoxide with formic acid resulted in the formation of stable deep blue radical, providing evidence of a disulfide group linked to the boron cage²⁶².

The reactions of $[\text{B}_{12}\text{H}_{11}\text{SH}]^{2-}$ with 4-methylbenzenesulfinyl chloride and 4-methylbenzenesulfonyl chloride in water gave the same product, $[\text{B}_{12}\text{H}_{11}\text{SSO}_2\text{C}_6\text{H}_4\text{CH}_3]^{2-}$. No evidence of the sulfide-sulfoxide was observed²⁴³.


Alkylation of the mercapto derivative with alkyl halides results, as a rule, in mixtures of the corresponding sulfide and sulfonium derivatives^{248,263,264} (Scheme 32).



SCHEME 32


The monoalkylated compounds are formed with secondary halides, such as 2-iodopropane, whereas primary halides give mixtures of mono- and dialkyl products. This approach was successfully used in synthesis of boron-containing porphyrins^{264,265} and glycosides^{229,265,266}.

The cyclic sulfonium derivative was obtained in the case of 1,4-dibromobutane²⁴⁸ (Scheme 33).




SCHEME 33

Alkylation of the dimercapto derivatives [1,2-, 1,7-, and 1,12-B₁₂H₁₀(SH)₂]²⁻ gives the corresponding bis(sulfonium) derivatives²⁶³ (Scheme 34).



SCHEME 34


It should be noted that other authors report successful preparation of the monoalkylated derivatives containing various functional groups^{267,268} (Scheme 35).



SCHEME 35

Alkylation of the [B₁₂H₁₁SH]²⁻ anion was used to produce the artificial host molecule for various oxoanions (sulfate, 4-nitrophenyl phosphate, squarate, croconate, rhodizonate)²⁶⁹⁻²⁷¹ (Fig. 6).

It was found that the cyanoethyl group can be easily removed from the sulfonium sulfur atom by treatment with alkali and therefore it could be used as a convenient protective group for synthesis of monoalkyl and unsymmetrical dialkyl derivatives of the [B₁₂H₁₁SH]²⁻ anion²⁴⁸ (Scheme 36).



SCHEME 36

The structure of the [B₁₂H₁₁SCH₂CH₂CN]²⁻ anion was determined by X-ray diffraction²⁷².

This approach has been successfully used in the synthesis of boron-rich building blocks for phosphodiester oligomers^{272,273}.

The dimethylsulfonium derivative $[B_{12}H_{11}SMe_2]^-$ was prepared by the treatment of the mercapto derivative with trimethylsulfonium iodide¹⁸⁹ (Scheme 37).



SCHEME 37

Another approach to the synthesis of the dimethylsulfonium derivatives consists in heating the *closo*-dodecaborate anion in dimethyl sulfoxide in the presence of acetic anhydride^{274,275} (Scheme 38).



SCHEME 38

By a suitable choice of temperatures and concentrations, yields as high as 90% of the desired products can be obtained. The dipropylsulfonium derivative $[B_{12}H_{11}SPr_2]^-$ was prepared in a similar way²⁷⁴.





FIG. 6
Artificial host molecule based on the mercapto-*closo*-dodecaborate anion

An alternative route to synthesis of the dialkylsulfonium derivatives is the pyrolysis of dialkyl sulfide–borane complexes^{8,9,276,277} or the reaction of the dimethyl sulfide–borane complex with decaborane⁸ (Scheme 39).




SCHEME 39

In all cases, the 1,7-isomer is the major component and only a small amount of the 1,2-isomer was isolated²⁷⁷.


Formation of the dimethyl sulfide derivatives [1,7- and 1,12-B₁₂H₁₀(SMe₂)₂] was also found in the reaction of the [B₁₂H₁₂]²⁻ anion with [PdCl₂(SMe₂)₂]²¹⁸.

The dimethylsulfonium derivative [B₁₂H₁₁SMe₂]⁻ can be partially demethylated by the treatment with potassium phthalimide in dimethylformamide, sodium ethylthiolate in ethanol, or alkali metal in liquid ammonia²⁷⁸. The second methyl group can be removed by the treatment with lithium metal in methylamine at -15 °C²⁶³. After some optimization of the [B₁₂H₁₁SMe₂]⁻ synthesis, this method can be in principle used for preparation of the mercapto derivative of the *closo*-dodecaborate anion (Scheme 40).




SCHEME 40

In a similar way, [1,2-, 1,7-, and 1,12-B₁₂H₁₀(SMe₂)₂] can be demethylated to the corresponding monoanions with potassium phthalimide in dimethylformamide, with butyllithium in ether, or with sodium ethylthiolate in ethanol. Using excess of potassium phthalimide or sodium ethylthiolate, the corresponding bis(methyl sulfide) derivative [1,2-, 1,7-, and 1,12-B₁₂H₁₀(SMe₂)₂]²⁻ were prepared. The same results can be obtained with an excess of alkali metal in liquid ammonia²⁷⁸. Reduction of the bis(dimethylsulfonium) derivatives with lithium metal in methylamine at -15 °C results in the corresponding dimercapto derivatives [1,2-, 1,7-, and 1,12-B₁₂H₁₀(SH)₂]²⁻²⁶³ (Scheme 41).



SCHEME 41

The methyl sulfide derivatives can be easily alkylated to give asymmetric sulfonium derivatives^{275,279,280} (Scheme 42).



SCHEME 42


The bromination of $[1,7\text{-B}_{12}\text{H}_{10}(\text{SMe}_2)_2]$ results in the formation of $[1,7\text{-(Me}_2\text{S)}_2\text{-9,10-Br}_2\text{-B}_{12}\text{H}_8]$ which resembles bromination of *m*-carborane. The monobromo derivative $[1,7\text{-(Me}_2\text{S)}_2\text{-9-Br-B}_{12}\text{H}_9]$ can be isolated as a major product from the reaction with one equivalent of brominating agent. The reaction of $[1,12\text{-B}_{12}\text{H}_{10}(\text{SMe}_2)_2]$ with excess of Me_2SBr_2 at room temperature results in the monobromo derivative $[1,12\text{-(Me}_2\text{S)}_2\text{-2-Br-B}_{12}\text{H}_9]$ ²⁷⁹.

The crystal and molecular structures of $(\text{Ph}_3\text{PMe})_2[\text{B}_{12}\text{H}_{11}\text{SMe}]^{2-}$, $(\text{Me}_3\text{S})\text{-}[\text{B}_{12}\text{H}_{11}\text{SMe}_2]\cdot\text{MeCN}$, $(\text{Ph}_3\text{PMe})[\text{1,7-Me}_2\text{SB}_{12}\text{H}_{10}\text{SMe}]^{2-}$, $[\text{1,2-B}_{12}\text{H}_{10}(\text{SMe}_2)_2]^{2-}$, $[\text{1,7-B}_{12}\text{H}_{10}(\text{SMe}_2)_2]^{2-}$, $[\text{1,12-B}_{12}\text{H}_{10}(\text{SMe}_2)_2]^{2-}$, and $[\text{1,2-B}_{12}\text{H}_{10}(\text{SCH}_2\text{Ph})_2]\cdot\text{CD}_3\text{CN}$ were determined by single-crystal X-ray diffraction.

Under basic conditions, the $[\text{B}_{12}\text{H}_{11}\text{SH}]^{2-}$ anion was shown to add to double bonds of Michael-type substrates giving the corresponding alkylsulfido derivatives²⁸⁰⁻²⁸².

The aryl sulfide derivative $[\text{B}_{12}\text{H}_{11}\text{SC}_6\text{H}_3\text{-2,4-(NO}_2)_2]^{2-}$ was obtained by the reaction of the dodecaborate anion with the 2,4-dinitrobenzenesulfonyl chloride²⁴³.


Acylation of the mercapto derivative with acyl halides in acetonitrile in the presence of pyridine gave the corresponding thioesters in high yields^{248,263} (Scheme 43).



SCHEME 43

The acetyl thioester $[\text{B}_{12}\text{H}_{11}\text{SC(O)Me}]^{2-}$ has been prepared also by heating of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion in thioacetic acid²²¹ and by the reaction of the *closo*-dodecaborate anion with acetylsulfonyl chloride²⁴³.


Oxidation of the methyl sulfide derivative $[\text{B}_{12}\text{H}_{11}\text{SMe}]^{2-}$ with hydrogen peroxide gives the corresponding methyl sulfone $[\text{B}_{12}\text{H}_{11}\text{SO}_2\text{Me}]^{2-}$, which can be reduced to the mercapto derivative with lithium in methylamine at -15°C ²⁶³ (Scheme 44).



SCHEME 44

Reactions of the methyl sulfide derivatives $[\text{B}_{12}\text{H}_{11}\text{SMe}]^{2-}$, $[\text{1,7(12)-Me}_2\text{SB}_{12}\text{H}_{10}\text{SMe}]^{2-}$, and $[\text{1,7(12)-B}_{12}\text{H}_{10}(\text{SMe})_2]^{2-}$ with hydroxylamine-*O*-sulfonic acid gave unexpectedly the corresponding amino-sulfonium salts $[\text{B}_{12}\text{H}_{11}\text{SMeNH}_2]^{2-}$, $[\text{1,7(12)-Me}_2\text{SB}_{12}\text{H}_{10}\text{SMeNH}_2]^{2-}$, and $[\text{1,7(12)-B}_{12}\text{H}_{10}(\text{SMeNH}_2)_2]^{2-}$ ²⁸⁰.

The thiocyanate derivative $[\text{B}_{12}\text{H}_{11}\text{SCN}]^{2-}$ was first prepared by the reaction of the parent *closo*-dodecaborate anion with $(\text{SCN})_2$ in dichloromethane^{283,284} (Scheme 45).



SCHEME 45


The alternative methods include the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with the thiocyanate ion under electrochemical and chemical oxidation conditions²⁸⁵. The thiocyanate group in $[\text{B}_{12}\text{H}_{11}\text{SCN}]^{2-}$ is very labile and cleaves easily in alkaline solution, by heating or UV irradiation²⁸⁴. The disubstituted derivatives $[1,7\text{- and }1,12\text{-B}_{12}\text{H}_{10}(\text{SCN})_2]^{2-}$ were obtained by the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with the thiocyanate ion under chemical oxidation conditions²⁸⁵.

Slow addition of ethanolic solution of iodine to aqueous solution of $[\text{B}_{12}\text{H}_{11}\text{SCN}]^{2-}$ results in formation of $[1\text{-I-}12\text{-NCS-B}_{12}\text{H}_{10}]^{2-}$ ²³⁸.

The crystal structures of $\text{Cs}_2[\text{B}_{12}\text{H}_{11}\text{SCN}]$ ²⁷⁹, $[(\text{Ph}_3\text{P})_2\text{N}]_2[1,7\text{-B}_{12}\text{H}_{10}(\text{SCN})_2]$ ²⁸⁵, $(\text{Et}_4\text{N})_2[1,12\text{-B}_{12}\text{H}_{10}(\text{SCN})_2]$ ²⁸⁵, and $(\text{Ph}_4\text{P})_2[1,12\text{-B}_{12}\text{H}_{10}(\text{I,SCN})_2]$ ²⁸⁶ were determined by X-ray diffraction.

9. DERIVATIVES WITH BORON-SELENIUM BOND

The selenocyanato derivative $[\text{B}_{12}\text{H}_{11}\text{SeCN}]^{2-}$ was prepared by the reaction of the *closo*-dodecaborate anion with $(\text{SeCN})_2$ in dichloromethane at $-100\text{ }^\circ\text{C}$ ²⁸⁷ and the reaction of the $[\text{B}_{12}\text{H}_{12}]^{2-}$ anion with selenocyanate anion under electrochemical oxidation conditions²⁸⁵. Crystal structure of $(\text{Ph}_4\text{P})_2[\text{B}_{12}\text{H}_{11}\text{SeCN}]$ was determined by X-ray diffraction²⁸⁷ (Scheme 46).



SCHEME 46

A series of metal salts of the unusual hexaselenoborato-*closo*-dodecaborate anion $[\text{B}_{12}(\text{BSe}_3)_6]^{8-}$ has been prepared by direct high-temperature solid-state synthesis from the corresponding metal selenides, boron, and selenium. The trigonal-planar BSe_3 selenoborate entities functioning as bidentate ligands complete the B_{12} icosahedron to form a persubstituted *closo*-dodecaborate anion (Fig. 7). The crystal structures of $\text{Cs}_8[\text{B}_{12}(\text{BSe}_3)_6]$, $\text{Rb}_8[\text{B}_{12}(\text{BSe}_3)_6]$, $\text{Cs}_4\text{Hg}_2[\text{B}_{12}(\text{BSe}_3)_6]$, and $\text{Rb}_4\text{Hg}_2[\text{B}_{12}(\text{BSe}_3)_6]$ were determined by single crystal diffraction^{288,289}. The other structure type was found in the sodium salt $\text{Na}_6[\text{B}_{18}\text{Se}_{17}]$: the neighbouring icosahedral B_{12} cluster entities saturated with trigonal-planar BSe_3 units are connected in

one direction *via* exocyclic selenium atoms forming the infinite chain anion $([\text{B}_{18}\text{Se}_{16}\text{Se}_{2/2}]^{6-})_Y^{290}$.

10. METALLO DERIVATIVES

The reactions of the *closo*-dodecaborate anion with mercury acetate and trifluoroacetate gave metallated derivatives $[\text{B}_{12}\text{H}_{12-n}(\text{HgOC}(\text{O})\text{CX}_3)_n]^{2-}$ ($\text{X} = \text{H, F; } n = 1-12$)^{291,292}. However, in contrast to the mercurated carborane derivatives²⁹³, the metallated dodecaborate derivatives are unstable and easily decompose in solution and in the solid state.

11. POTENTIAL APPLICATIONS OF *closo*-DODECABORATE DERIVATIVES

If we try to survey possible directions of application of the *closo*-dodecaborate anion and its derivatives, the military direction should be mentioned as the first one. The interest in high boron hydrides as high energy density materials, which arose at the time of Project ZIP, still persists. In this field the *closo*-dodecaborate anion takes advantage of high stability under usual conditions that allows to use its salts as components of high burning composite propellants²⁹⁴⁻²⁹⁶. An important field is using lithium *closo*-dodecaborates $\text{Li}_2[\text{B}_{12}\text{H}_{12}]$ and $\text{Li}_2[\text{B}_{12}\text{Cl}_{12}]$ as nonaqueous electrolytes for advanced rechargeable lithium batteries^{149,297-300}. Among the other fields of potential application of the *closo*-dodecaborate derivatives, we could mention thermally stable polymers¹⁷², non-linear optics materials³⁰¹,




FIG. 7
Structure of the $[\text{B}_{12}(\text{BSe}_3)_6]^{2-}$ anion

extractants for purification of nuclear wastes^{185,235}, ion-selective electrodes³⁰², manufacture of boron carbide³⁰³, catalysts for organic synthesis³⁰⁴, etc. However, the main direction of application of the *closo*-dodecaborate derivatives nowadays is medicine³⁰⁵.

The possibility of the application of the *closo*-dodecaborate anion in medicine is based on its remarkable chemical and hydrolytical stability and low toxicity. The sodium salt $\text{Na}_2[\text{B}_{12}\text{H}_{12}]$ administered orally to rats was found to have a low order of acute toxicity, with the approximate lethal dose for rats >7.5 g/kg of body weight which is roughly comparable to that of sodium chloride³⁸.

The leading position in application of polyhedral boron hydrides in medicine belongs to Boron Neutron Capture Therapy (BNCT) – a binary cancer treatment based upon the interaction of two relatively harmless species, a ^{10}B nucleus and a thermal neutron. Capture of the thermal neutron by the ^{10}B nucleus results in the formation of an excited ^{10}B nucleus which decays to yield highly energetic ^4He and ^7Li as products. Each of these fission products has an effective range of ≈ 10 μm in tissue, thus effectively limiting the extent of cell damage to approximately one cell diameter. Therefore, the selective concentration of the ^{10}B nuclei within tumor cells, followed by their capture of thermal neutrons, should result in localized destruction of the malignant cells in the presence of the neighboring normal cells³⁰⁶⁻³⁰⁹.

The main advantages of the *closo*-dodecaborate anion and its derivatives, in comparison with the extensively explored carborane derivatives, are their high water solubility as sodium salts and simple methods of the parent anion synthesis from ^{10}B -enriched raw material. It should be noted that sodium borocaptate $\text{Na}_2[\text{B}_{12}\text{H}_{11}\text{SH}]$ is one of two clinically used BNCT agents.

Although most BNCT research has been focused mainly on malignant tumor cells, this general approach is applicable to any diseased tissue of localized nature. Rheumatoid arthritis (RA) afflicts more than 1% of the adult population and is the most common cause of chronic inflammatory synovitis. The application of BNCT in the treatment of arthritis (boron neutron capture synovectomy) has been proposed³¹⁰.

The *closo*-dodecaborate cage could be used also as a linker for the introduction of a radiohalogen label into biomolecules for radioimmuno-diagnostics and radioimmunotherapy. Radioactive halogen isotopes play an important role in nuclear medicine. ^{123}I is widely used for gamma-scintigraphy and single-photon emission computerized tomography, and ^{131}I is currently the main radionuclide for radioisotope therapy. There is an increasing interest in application of positron emission tomography in stud-

ies of large biomolecules such as monoclonal antibodies, their fragments and shorter peptides, which necessitates the use of positron-emitting halogens like ^{76}Br and ^{124}I . The α -emitting halogen ^{211}At is considered to be one of the most promising therapeutical nuclides in the near future. However, there is a serious problem in the medical application of radiohalogens, "dehalogenation", *i.e.*, the relatively rapid release of radioactivity from the cells after intracellular processing of the labelled compound.

The feasibility of labelling the parent *closo*-dodecaborate anion with different radiohalogen isotopes has been shown recently and the high stability of the radiohalogen label *in vivo* has been demonstrated³¹¹⁻³¹⁷. Recently the isothiocyanate derivative $[\text{B}_{12}\text{H}_{11}\text{NH}_2\text{CH}_2\text{C}_6\text{H}_4\text{-4-NCS}]^-$ was proposed as linker for indirect radioiodination and radiobromination of proteins^{318,319}.

Another possibility of medical application of the *closo*-dodecaborate anion is X-ray contrasting imaging. Highly iodinated molecules have been used in medicine as X-ray contrast agents due to the opacity of iodine atoms to low-energy X-rays³²⁰. Even with the recent phenomenal growth of Magnetic Resonance Imaging and ultrasound procedures, X-ray imaging studies remain the workhorse of modern radiology (currently 75-80% of all diagnostic imaging procedures are X-ray related). Today, iodinated X-ray contrast agents are used in about 20 million procedures annually in the U.S.A., mainly in computing tomography and angiographic applications. Sales of these agents in the U.S.A. exceeded \$550 million in 1997³²¹.

Current X-ray contrast agents are composed of substituted iodinated benzene compounds and their dimers. Most of the iodinated benzene derivatives have three iodine atoms substituted in an alternating fashion with other substituents which are designed to increase water solubility and decrease *in vivo* toxicity. Although the current radiographic contrast media have been optimized over many years of development, improvements are still being sought. A method of improving contrast agents is to increase the iodine content in the molecules. It is known that an increase in the percentage of iodine in a contrast agent from 28.7 to 37.5% doubles the contrast of the radiographic image at selected X-ray energies. This fact suggests that chemical moieties other than benzene rings, which can be more highly iodinated, might present new alternatives for contrast agents. The *closo*-dodecaborate cage can be easily halogenated and have the potential of incorporation of a large number of iodine atoms per molecule (compounds containing 65-85 wt.% of iodine can be obtained)^{322,323}.

Besides the above-mentioned general applications of the *closo*-dodecaborate derivatives, some of them have specific physiological activity. It has

been found that alkylammonium dodecaborates are potent hypolipidemic³²⁴ and antineoplastic³²⁵ agents.

The authors thank INTAS (99-00806), the Russian Foundation for Basic Research (02-03-32192), the Royal Swedish Academy of Science, the Swedish Cancer Society, and the Carl Tryggers Foundation for financial support.

REFERENCES

1. Stock A.: *Hydrides of Boron and Silicon*. Cornell University Press, Ithaca (NY) 1933.
2. Eberhardt W. H., Crawford B., Lipscomb W. N.: *J. Chem. Phys.* **1954**, *22*, 989.
3. Lipscomb W. H.: *Boron Hydrides*. W. A. Benjamin, New York 1963.
4. Williams R. E.: *Inorg. Chem.* **1971**, *10*, 210.
5. Williams R. E.: *Adv. Inorg. Chem. Radiochem.* **1976**, *18*, 67.
6. Longuet-Higgins H. C., Roberts M. de V.: *Proc. R. Soc. London, Ser. A* **1955**, *230*, 110.
7. Hawthorne M. F., Pitochelli A. R.: *J. Am. Chem. Soc.* **1960**, *82*, 3228.
8. Miller H. C., Miller N. E., Muetterties E. L.: *Inorg. Chem.* **1964**, *3*, 1456.
9. Miller H. C., Miller N. E., Muetterties E. L.: *J. Am. Chem. Soc.* **1963**, *85*, 3885.
10. Greenwood N. N., Morris J. H.: *Proc. Chem. Soc.* **1963**, 338.
11. Adams R. M., Siedle A. R., Grant J.: *Inorg. Chem.* **1964**, *3*, 461.
12. Ellis I. A., Gaines D. F., Schaeffer R.: *J. Am. Chem. Soc.* **1963**, *85*, 3885.
13. Briguglio J. J., Carroll P. J., Corcoran E. W., Sneddon L. G.: *Inorg. Chem.*, **1986**, *25*, 4618.
14. Miller H. C., Muetterties E. L.: *Inorg. Synth.* **1967**, *10*, 88.
15. Kuznetsov N. T., Klimchuk G. S.: *Russ. J. Inorg. Chem.* **1971**, *16*, 645.
16. Kuznetsov N. T., Klimchuk G. S. in: *Khimiya i Khimicheskaya Tekhnologiya* (A. N. Bashkirov, Ed.), p. 286. Mosk. Inst. Tonkoi Khim. Tekhnol., Moscow 1972.
17. Volkov V. V., Posnaya I. S.: *Izv. Sib. Otd. Akad. Nauk SSSR, Ser. Khim. Nauk* **1979**, *4(9)*, 88.
18. Volkov V. V., Posnaya I. S.: *Russ. J. Inorg. Chem.* **1979**, *24*, 1571.
19. Volkov V. V., Posnaya I. S.: *Izv. Akad. Nauk SSSR, Ser. Khim.* **1980**, 400.
20. Manhlouf J. M., Hough W. V., Hefferan G. T.: *Inorg. Chem.* **1967**, *6*, 1196.
21. Guillevic G., Dazord J., Mongeot H., Cueilleron J.: *J. Chem. Res.* **1978**, 402.
22. Mongeot H., Bonnetot B., Atchekzai J., Colombier M., Vigot-Vieillard C.: *Bull. Soc. Chim. Fr.* **1986**, 385.
23. Colombier M., Mongeot H., Bonnetot B.: *Bull. Soc. Chim. Fr.* **1988**, 844.
24. Titov L. V., Eremin E. R., Rosolovskii V. Ya.: *Russ. J. Inorg. Chem.* **1982**, *27*, 500.
25. Wang F., Wang Y., Wang X.: *Yingyong Huaxue* **1998**, *15(5)*, 111; *Chem. Abstr.* **1999**, 130, 75355.
26. Klanberg F., Mueterties E. L.: *Inorg. Chem.* **1966**, *5*, 1955.
27. Titov L. V., Levicheva M. D., Psikha S. B.: *Russ. J. Inorg. Chem.* **1984**, *29*, 386.
28. Bonnetot B., Frange B., Mongeot H., El Shamy S., Ouassas A., R'kha C.: *Bull. Soc. Chim. Fr.* **1989**, 632.
29. Dyson P. J., Hill A. F., Hulkes A. G., White A. J. P., Williams D. J.: *Angew. Chem., Int. Ed.* **1998**, *37*, 1430.
30. Mal'tseva N. N., Shishkin Yu. L., Golovanova A. I., Kuznetsov N. T.: *Dokl. Chem.* **1997**, *357*, 280.

31. Grüner B., Procházka V., Šubrt J., Heřmánek S., Pospěch R.: *Eur. J. Solid State Inorg. Chem.* **1991**, 28, 597.
32. Harzdorf C., Niederprüm H., Oclenbach H.: *Z. Naturforsch., Chem. Sci.* **1970**, 25, 6.
33. Solntsev K. A., Saldin V. I., Kuznetsov N. T.: U.S.S.R. 1,695,619; *Chem. Abstr.* **2000**, 133, 32399.
34. Agafonov A. V., Solntsev K. A., Kuznetsov N. T.: *Koord. Khim.* **1980**, 6, 1767.
35. Vinitskii D. M., Lagun V. L., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1984**, 29, 1079.
36. Kabbani R. M.: *Polyhedron* **1996**, 15, 1951.
37. Volkov O., Dirk W., Englert U., Paetzold P.: *Z. Anorg. Allg. Chem.* **1999**, 625, 1193.
38. Muetterties E. L., Balthis J. H., Chia Y. T., Knoth W. H., Miller H. C.: *Inorg. Chem.* **1964**, 3, 444.
39. Kuznetsov N. T., Solntsev K. A., Kulikova L. N.: *Koord. Khim.* **1976**, 2, 1874.
40. Benham V., Lord G., Butler I. S., Gilson D. F. R.: *Appl. Spectrosc.* **1987**, 41, 915.
41. Klimchuk G. S., Kuznetsov N. T.: *Tr. Mosk. Inst. Tonkoi Khim. Tekhnol.* **1972**, 2(2), 19; *Chem. Abstr.* **1974**, 80, 33350.
42. Kuznetsov N. T., Solntsev K. A., Klimchuk G. S.: *Izv. Akad. Nauk SSSR, Neorg. Mat.* **1978**, 14, 2013.
43. Solntsev K. A., Kuznetsov N. T., Kol'ba L. N., Agre V. M., Ponomarev V. I.: *Russ. J. Inorg. Chem.* **1977**, 22, 171.
44. Kanaeva O. A., Kuznetsov N. T.: *Tr. Mosk. Inst. Tonkoi Khim. Tekhnol.* **1972**, 2(2), 21; *Chem. Abstr.* **1974**, 80, 33351.
45. Gaft Yu. L., Zhukov S. T., Kuznetsov N. T.: *Tr. Mosk. Inst. Tonkoi Khim. Tekhnol.* **1975**, 5(1), 11; *Chem. Abstr.* **1977**, 86, 50026.
46. Kuznetsov N. T., Zemskova L. A., Goeva L. V.: *Koord. Khim.* **1981**, 7, 232.
47. Malinina E. A., Mustyatsa V. N., Goeva L. V., Filippova T. V., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **2001**, 46, 1137.
48. Kuznetsov N. T., Kulikova L. N., Kanaeva O. A.: *Zh. Anal. Khim.* **1976**, 31, 1382.
49. Kanaeva O. A., Klimchuk G. S., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1987**, 32, 450.
50. Malinina E. A., Goeva L. V., Solntsev K. A., Kuznetsov N. T.: *Sov. J. Coord. Chem.* **1992**, 18, 332.
51. Malinina E. A., Goeva L. V., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1991**, 36, 1361.
52. Orlova A. M., Mustyatsa V. N., Goeva L. V., Katser S. B., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1996**, 41, 1856.
53. Malinina E. A., Goeva L. V., Votnova N. A., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1994**, 39, 1997.
54. Malinina E. A., Goeva L. V., Ivanov S. V., Solntsev K. A., Kuznetsov N. T.: *Sov. J. Coord. Chem.* **1992**, 18, 329.
55. Orlova A. M., Mustyatsa V. N., Goeva L. V., Katser S. B., Lagun V. L., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1996**, 41, 1525.
56. Kuznetsov N. T., Kulikova L. N., Kanaeva O. A.: *Zh. Anal. Khim.* **1976**, 31, 2447.
57. Kanaeva O. A., Kuznetsov N. T., Voronina S. A., Sosnovskaya O. O.: *Russ. J. Inorg. Chem.* **1978**, 23, 1858.
58. Kanaeva O. A., Kuznetsov N. T., Sosnovskaya O. O.: *Russ. J. Inorg. Chem.* **1981**, 26, 625.
59. Kanaeva O. A., Kuznetsov N. T., Sosnovskaya O. O.: *Russ. J. Inorg. Chem.* **1978**, 23, 1591.
60. Kanaeva O. A., Kuznetsov N. T., Sosnovskaya O. O.: *Russ. J. Inorg. Chem.* **1986**, 31, 1848.

61. Kanaeva O. A., Kuznetsov N. T., Sosnovskaya O. O.: *Russ. J. Inorg. Chem.* **1978**, 23, 1592.
62. Kuznetsov N. T., Klimchuk G. S., Kanaeva O. A.: *Russ. J. Inorg. Chem.* **1975**, 20, 1416.
63. Kuznetsov N. T., Klimchuk G. S., Kanaeva O. A., Solntsev K. A.: *Russ. J. Inorg. Chem.* **1976**, 21, 505.
64. Solntsev K. A., Kuznetsov N. T., Trunov V. K., Karpinskii O. G., Klimchuk G. S., Uspenskaya S. I., Oboznenko Yu. V.: *Russ. J. Inorg. Chem.* **1977**, 22, 1744.
65. Kanaeva O. A., Kuznetsov N. T., Sosnovskaya O. O., Goeva L. V.: *Russ. J. Inorg. Chem.* **1980**, 25, 1315.
66. Kanaeva O. A., Kuznetsov N. T., Solntsev K. A.: *Russ. J. Inorg. Chem.* **1990**, 35, 1421.
67. Titov L. V., Eremin E. R., Dubikhina G. N., Rosolovskii V. Ya.: *Izv. Akad. Nauk SSSR, Ser. Khim.* **1982**, 255.
68. Gaft Yu. L., Kuznetsov N. T., Sukova L. M.: *Russ. J. Inorg. Chem.* **1983**, 28, 89.
69. Zhang L., He D., Zhang K., Zhang G.: *Wuhan Daxue Xuebao, Ziran Kexueban* **1984** (3), 65; *Chem. Abstr.* **1985**, 103, 105032.
70. Kayumov A. G., Goeva L. V., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1988**, 33, 680.
71. Kayumov A. G., Solntsev K. A., Goeva L. V., Kuznetsov N. T., Ellert O. G.: *Russ. J. Inorg. Chem.* **1988**, 33, 1007.
72. Kayumov A. G., Solntsev K. A., Goeva L. V., Kuznetsov N. T., Ellert O. G.: *Russ. J. Inorg. Chem.* **1988**, 33, 1103.
73. Kayumov A. G., Yakushev A. B., Solntsev K. A., Goeva L. V., Kuznetsov N. T., Ellert O. G.: *Russ. J. Inorg. Chem.* **1988**, 33, 1482.
74. Kayumov A. G., Solntsev K. A., Goeva L. V., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1990**, 35, 985.
75. Zhang L., Zhang Y., Wu M., He D., Zhang G.: *Gaodeng Xuexiao Huaxue Xuebao* **1984**, 5, 287; *Chem. Abstr.* **1984**, 101, 211433.
76. Zhang L., Chen X., Li E., He J.: *Youji Huaxue* **1984**, 446; *Chem. Abstr.* **1985**, 102, 132108.
77. Zhang L., Huang Y., Chen X., He J.: *Gaodeng Xuexiao Huaxue Xuebao* **1985**, 6, 872; *Chem. Abstr.* **1986**, 105, 191365.
78. Kunkely H., Vogler A.: *Collect. Czech. Chem. Commun.* **2001**, 66, 119.
79. Harris T. V., Rathke J. W., Muettterties E. L.: *J. Am. Chem. Soc.* **1978**, 100, 6966.
80. Volkov V. V., Il'inchik E. A., Voronina G. S., Volkov O. V., Ikorskii V. N.: *Russ. J. Inorg. Chem.* **1995**, 40, 772.
81. Zhang G., Zhu H., Ding Q. in: *Fundam. Res. Organomet. Chem., Proc. 1st China-Jpn.-U.S. Trilateral Semin. Organomet. Chem. 1980* (M. Tsutsui, Y. Ishii and Y. Huang, Eds), p. 771. Van Nostrand Reinhold, New York 1982.
82. Zhang G., Zhu H., Ding Q.: *Gaodeng Xuexiao Huaxue Xuebao* **1982**, 3, 351; *Chem. Abstr.* **1983**, 98, 34717.
83. Zhang L., Hu. P., Zhang G.: *Youji Huaxue* **1983**, 277; *Chem. Abstr.* **1984**, 100, 51782.
84. Zhang G., Zhang Zh., Zhang Y., Chen Z.: *Wuhan Daxue Xuebao, Ziran Kexueban* **1984** (1), 95; *Chem. Abstr.* **1985**, 102, 24770.
85. Zhang L., Zhang Y., Wu M., He D., Zhang G.: *Gaodeng Xuexiao Huaxue Xuebao* **1984**, 5, 287; *Chem. Abstr.* **1984**, 101, 211433.
86. Zhang G., Zhu H., Ding Q.: *Yingyong Huaxue* **1985**, 2(1), 70; *Chem. Abstr.* **1985**, 103, 215362.
87. Zhang L., Fang X., Zhang G.: *Gaodeng Xuexiao Huaxue Xuebao* **1985**, 6, 663; *Chem. Abstr.* **1986**, 105, 43030.

88. Zhang L., Hu P., Xiang J., Zhang G.: *Wuhan Daxue Xuebao, Ziran Kexueban* **1985** (2), 59; *Chem. Abstr.* **1986**, 105, 191341.
89. He J., Sun L., Chen X., Zhang L.: *Gaodeng Xuexiao Huaxue Xuebao* **1992**, 13, 686; *Chem. Abstr.* **1993**, 118, 59861.
90. Elrington M., Greenwood N. N., Kennedy J. D., Thornton-Pett M.: *J. Chem. Soc., Dalton Trans.* **1987**, 451.
91. Lagun V. L., Orlova A. M., Katser S. B., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Coord. Chem.* **1994**, 20, 406.
92. Lagun V. L., Solntsev K. A., Katser S. B., Orlova A. M., Kuznetsov N. T.: *Russ. J. Coord. Chem.* **1994**, 20, 475.
93. Orlova A. M., Goeva L. V., Lagun V. L., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1996**, 41, 377.
94. Zhang L., Hu P., Chang G.: *Wuhan Daxue Xuebao, Ziran Kexueban* **1989** (2), 67; *Chem. Abstr.* **1990**, 113, 40457.
95. Weng F., Yin Z., Long X.: *Guangxi Daxue Xuebao, Ziran Kexueban* **1999**, 24(1), 54; *Chem. Abstr.* **2000**, 132, 101779.
96. White J. P., III, Deng H., Boyd E. P., Gallucci J., Shore S. G.: *Inorg. Chem.* **1994**, 33, 1685.
97. Zhang L., Hu P., Zhang G.: *Zhongguo Xitu Xuebao* **1984**, 2(2), 26; *Chem. Abstr.* **1986**, 104, 14029.
98. Zhang L., Hu P., Qian Ch., Zhang G.: *Gaodeng Xuexiao Huaxue Xuebao* **1984**, 5, 153; *Chem. Abstr.* **1984**, 100, 220544.
99. Zhang G., Xiong H., Zhang L.: *Yingyong Huaxue* **1984**, 1(5), 40; *Chem. Abstr.* **1985**, 103, 63832.
100. Zhang L., Hu P., Gao X.: *Wuji Huaxue* **1986**, 2(1), 60; *Chem. Abstr.* **1986**, 107, 88373.
101. Hu P., Zhang L., Ji L., Zheng X.: *Zhongguo Xitu Xuebao* **1990**, 8, 301; *Chem. Abstr.* **1992**, 116, 267829.
102. Chen X., Jiang J., Zhan L.: *Zhongguo Xitu Xuebao* **1988**, 6, 13; *Chem. Abstr.* **1989**, 110, 224377.
103. Li E., Guo K., Xu G., Zhang L., Hu P.: *Huaxue Tongbao* **1985** (1), 13; *Chem. Abstr.* **1985**, 102, 212070.
104. Wang D., Li E., Xu G., Zhang L.: *Chin. Sci. Bull.* **1990**, 35, 103.
105. Kuznetsov N. T., Zemskova L. A., Alikhanova Z. M., Ippolitov E. G.: *Russ. J. Inorg. Chem.* **1981**, 26, 715.
106. Kuznetsov N. T., Zemskova L. A., Ippolitov E. G.: *Russ. J. Inorg. Chem.* **1981**, 26, 1003.
107. Kuznetsov N. T., Zemskova L. A., Ippolitov E. G.: *Russ. J. Inorg. Chem.* **1981**, 26, 1343.
108. Kuznetsov N. T., Zemskova L. A.: *Russ. J. Inorg. Chem.* **1983**, 28, 743.
109. Orlova A. M., Solntsev K. A., Kuznetsov N. T., Alikhanova Z. M., Goeva L. V.: *Russ. J. Inorg. Chem.* **1988**, 33, 1023.
110. Strauss S.: *Chem. Rev. (Washington, D. C.)* **1993**, 93, 927.
111. Reed C.: *Acc. Chem. Res.* **1998**, 31, 133.
112. Shubina E. S., Tikhonova I. A., Bakhmutova E. V., Dolgushin F. M., Antipin M. Yu., Bakhmutov V. I., Sivaev I. B., Teplitskaya L. N., Chizhevskii I. T., Pisareva I. V., Bregadze V. I., Epstein L. M., Shur V. B.: *Chem. Eur. J.* **2001**, 7, 3783.
113. Zakharova I. A.: *Coord. Chem. Rev.* **1982**, 43, 313.
114. Solntsev K. A., Kuznetsov N. T., Ponomarev V. I.: *Dokl. Chem.* **1976**, 228, 391.

115. Ponomarev V. I., Lyubeznova T. Yu., Solntsev K. A., Kuznetsov N. T.: *Koord. Khim.* **1991**, 17, 21.
116. Wunderlich J. A., Lipscomb W. N.: *J. Am. Chem. Soc.* **1960**, 82, 4427.
117. Uspenskaya S. T., Solntsev K. A., Kuznetsov N. T.: *Zh. Strukt. Khim.* **1975**, 16, 482.
118. Tiritiris I., Schleid T., Müller K., Preetz W.: *Z. Anorg. Allg. Chem.* **2000**, 626, 323.
119. Solntsev K. A., Kuznetsov N. T., Ponomarev V. I.: *Izv. Akad. Nauk SSSR, Neorg. Mat.* **1976**, 12, 1044.
120. Tiritiris I., Schleid T.: *Z. Anorg. Allg. Chem.* **2001**, 627, 1836.
121. Solntsev K. A., Kuznetsov N. T., Rannev N. V., Zavodnik V. E.: *Dokl. Akad. Nauk SSSR* **1977**, 232, 1366.
122. Solntsev K. A., Kuznetsov N. T., Rannev N. V.: *Dokl. Akad. Nauk SSSR* **1975**, 221, 1378.
123. Mikhailov Yu. N., Kanishcheva A. S., Zemsikova L. A., Mistryukov V. E., Kuznetsov N. T., Solntsev K. A.: *Russ. J. Inorg. Chem.* **1982**, 27, 1321.
124. Katser S. B., Malinina E. A., Mustyatsa V. N., Solntsev K. A., Kuznetsov N. T.: *Koord. Khim.* **1992**, 18, 387.
125. Hofmann K., Albert B.: *Z. Anorg. Allg. Chem.* **2001**, 627, 1055.
126. Shoham G., Schomburg D., Lipscomb W.: *Cryst. Struct. Commun.* **1980**, 9, 429.
127. Fu Zh., Cai Zh., Pan K., Zhang L.: *Jiegou Huaxue* **1984**, 3, 231; *Chem. Abstr.* **1985**, 103, 132769.
128. Chen L., Pan K., Chen X., Zhang L.: *Jiegou Huaxue* **1984**, 3, 125; *Chem. Abstr.* **1985**, 103, 62903.
129. Zhang Y., Chen Zh., Cai Zh., Pan K., Zhang G., Zhang Zh.: *Jiegou Huaxue* **1983**, 2, 201; *Chem. Abstr.* **1984**, 101, 120821.
130. Chen L., Pan K., Lun Zh., Hu P.: *Jiegou Huaxue* **1984**, 3, 1; *Chem. Abstr.* **1987**, 106, 166639.
131. Chen L., Pan K., Lun Zh., Hu P.: *Jiegou Huaxue* **1984**, 3, 5; *Chem. Abstr.* **1987**, 106, 166640.
132. Wiersema R. J., Middaugh R. L.: *Inorg. Chem.* **1969**, 8, 2074.
133. Aihara J.: *J. Am. Chem. Soc.* **1978**, 100, 3339.
134. King R. B.: *Chem. Rev. (Washington, D. C.)* **2001**, 101, 1119.
135. Knoth W. H., Miller H. C., Sauer J. C., Balthis J. H., Chia Y. T., Muettterties E. L.: *Inorg. Chem.* **1964**, 3, 159.
136. Zhukova N. A., Kuznetsov N. T., Solntsev K. A., Ustyniuk Yu. A., Grishin Yu. K.: *Russ. J. Inorg. Chem.* **1980**, 25, 378.
137. Zhukova N. A., Kuznetsov N. T., Solntsev K. A.: *Russ. J. Inorg. Chem.* **1980**, 25, 513.
138. Zhukova N. A., Kuznetsov N. T., Solntsev K. A.: *Russ. J. Inorg. Chem.* **1980**, 25, 1618.
139. Solntsev K. A., Mebel A. M., Votina N. A., Kuznetsov N. T., Charkin O. P.: *Russ. J. Coord. Chem.* **1992**, 18, 296.
140. Thomsen H., Haeckel O., Krause U., Preetz W.: *Z. Anorg. Allg. Chem.* **1996**, 622, 2061.
141. Solntsev K. A., Ivanov S. V., Sakharov S. G., Katser S. B., Chernyavskii A. S., Votina N. A., Klyuchishche E. A., Kuznetsov N. T.: *Russ. J. Coord. Chem.* **1997**, 23, 369.
142. Zhukova N. A., Malinina E. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1985**, 30, 735.
143. a) Ivanov S. V., Lupinetti A. J., Solntsev K. A., Strauss S. H.: *J. Fluorine Chem.* **1998**, 89, 65; b) Strauss S. H., Ivanov S. V.: Private communication.
144. Solntsev K. A., Zhukova N. A., Butman L. A., Kuznetsov N. T.: *Izv. Akad. Nauk SSSR, Neorg. Mat.* **1980**, 16, 1882.
145. Haeckel O., Preetz W.: *Z. Anorg. Allg. Chem.* **1995**, 621, 1454.

146. Srebný H.-G., Preetz W.: *Z. Naturforsch., B: Chem. Sci.* **1984**, 39, 189.
147. Grüner B., Heřmánek S., Plzák Z.: *VII Int. Meet. Boron Chem. IMEBORON*, Book of Abstracts, p. 5. Torun 1990.
148. Grüner B., Plzák Z., Vinš I.: *J. Chromatogr.* **1991**, 588, 201.
149. Johnson J. W., Brody J. F.: *J. Electrochem. Soc.* **1982**, 129, 2213.
150. Rupich M. W., Foos J. S., Brummer S. B.: *J. Electrochem. Soc.* **1985**, 132, 119.
151. Kuznetsov N. T., Kulikova L. N., Zhukov S. T.: *Russ. J. Inorg. Chem.* **1976**, 21, 51.
152. Trofimenko S.: *J. Am. Chem. Soc.* **1966**, 88, 1899.
153. Tiritiris I., Schleid T.: *Z. Anorg. Allg. Chem.* **2001**, 627, 2568.
154. Kulikova L. N., Kuznetsov N. T., Lappo I. V., Zhukov S. T.: *Russ. J. Inorg. Chem.* **1976**, 21, 509.
155. Kuznetsov N. T., Kulikova L. N., Faerman V. I.: *Izv. Akad. Nauk SSSR, Neorg. Mat.* **1976**, 12, 1212. (Engl. Transl., 1012).
156. Kuznetsov N. T., Kulikova L. N.: *Izv. Akad. Nauk SSSR, Neorg. Mat.* **1980**, 16, 1403.
157. Knoth W. H.: *Inorg. Chem.* **1975**, 14, 1566.
158. Sievert A. C., Muettterties E. L.: *Inorg. Chem.* **1981**, 20, 489.
159. Gaft Yu. L., Zakharova I. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1980**, 25, 726.
160. Gaft Yu. L., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1981**, 26, 699.
161. Zhang L., Hu P., Xiang J., Zhang G.: *Wuhan Daxue Xuebao, Ziran Kexueban* **1985** (2), 59; *Chem. Abstr.* **1986**, 105, 191341.
162. Knoth W. H., Sauer J. C., Miller H. C., Muettterties E. L.: *J. Am. Chem. Soc.* **1964**, 86, 115.
163. Knoth W. H., Sauer J. C., Balthis J. H., Miller H. C., Muettterties E. L.: *J. Am. Chem. Soc.* **1967**, 89, 4842.
164. Fox M. A., Howard J. A. K., Moloney J. M., Wade K.: *Chem. Commun.* **1998**, 2487.
165. Brint P., Sangchakr B., McGrath M., Spalding T. R., Suffolk R. J.: *Inorg. Chem.* **1990**, 29, 47.
166. Dewar M. J. C., McKee M. L.: *Inorg. Chem.* **1978**, 17, 1569.
167. Hansen L. D., Partridge J. A., Izatt R. M., Christensen J. J.: *Inorg. Chem.* **1966**, 5, 569.
168. Alam F., Soloway A. H., Barth R. F., Mafune N., Adams D. M., Knoth W. H.: *J. Med. Chem.* **1989**, 32, 2326.
169. Knoth W. H., Miller N. E., Hertler W. R.: *Inorg. Chem.* **1967**, 6, 1977.
170. Haslinger F., Soloway A. H., Butler D. N.: *J. Med. Chem.* **1966**, 9, 581.
171. Schaeffgen J., Miller H. C., Sauer J. C., Sharkey W. H.: *J. Polym. Sci., Part A-1* **1971**, 9, 51.
172. Hertler W. R., Raasch M. S.: *J. Am. Chem. Soc.* **1964**, 86, 3661.
173. King G. T., Miller N. E.: *Inorg. Chem.* **1986**, 25, 4309.
174. Hertler W. R., Knoth W. H., Muettterties E. L.: *J. Am. Chem. Soc.* **1964**, 86, 5434.
175. a) Sivaev I. B., Bregadze V. I., Sjöberg S.: *Russ. Chem. Bull.* **1998**, 47,193; b) Sivaev I. B.: *Thesis*. Uppsala University, Uppsala 2000.
176. Zhizhin K. Yu., Goeva L. V., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **2002**, 47, 341.
177. Hertler W. R., Knoth W. H., Muettterties E. L.: *Inorg. Chem.* **1965**, 4, 288.
178. Semioshkin A. A., Petrovskii P. V., Gabel D., Brellochs B., Bregadze V. I.: *Russ. Chem. Bull.* **1998**, 47, 980.
179. Preetz W., von Bismarck R.: *J. Organomet. Chem.* **1991**, 411, 25.
180. von Bismarck R., Preetz W.: *J. Organomet. Chem.* **1991**, 418, 147.
181. von Bismarck R., Preetz W.: *J. Organomet. Chem.* **1991**, 418, 157.
182. Koch T., Preetz W.: *Z. Naturforsch., B: Chem. Sci.* **1997**, 52, 935.

183. Peymann T., Knobler C. B., Hawthorne M. F.: *Inorg. Chem.* **1998**, *37*, 1544.
184. Zakharkin L. I., Zhigareva G. L.: *Russ. J. Gen. Chem.* **2001**, *71*, 83.
185. Grüner B., Bonnetot B., Mongeot H.: *Collect. Czech. Chem. Commun.* **1997**, *62*, 1185.
186. Peymann T., Knobler C. B., Hawthorne M. F.: *J. Am. Chem. Soc.* **1999**, *121*, 5601.
187. Peymann T., Knobler C. B., Hawthorne M. F.: *Chem. Commun.* **1999**, 2039.
188. Knoth W. H., Miller H. C., England D. C., Parshall G. W., Muettterties E. L.: *J. Am. Chem. Soc.* **1962**, *84*, 1056.
189. Knoth W. H., Sauer J. C., England D. C., Hertler W. R., Muettterties E. L.: *J. Am. Chem. Soc.* **1964**, *86*, 3973.
190. Harmon A. B., Harmon K. M.: *J. Am. Chem. Soc.* **1966**, *88*, 4093.
191. Harmon K. M., Harmon A. B., MacDonald A. A.: *J. Am. Chem. Soc.* **1969**, *91*, 323.
192. a) Harmon K. M., Nelson T. E., Stachoeski B. M.: *J. Mol. Struct.* **1995**, *350*, 135; b) Harmon K. M., Gill S. H.: *J. Mol. Struct.* **2002**, *607*, 181.
193. Trofimenko S.: *J. Am. Chem. Soc.* **1965**, *87*, 653.
194. Dudenkov I. B., Zhizhin K. Yu., Chernyavskii A. S., Katser S. B., Goeva L. V., Sergienko V. S., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **2000**, *45*, 1864.
195. Nakagawa T., Aono K.: *Chem. Pharm. Bull.* **1976**, *24*, 778.
196. Peymann T., Lork E., Schmidt M., Nöth H., Gabel D.: *Chem. Ber.* **1997**, *130*, 795.
197. Zhizhin K. Yu., Malinina E. A., Goeva L. V., Chernyavskii A. S., Ivanov S. V., Lukyanets E. A., Solntsev K. A., Kuznetsov N. T.: *Dokl. Chem.* **1997**, *357*, 260.
198. Spryshkova R., Grigorieva E., Riabkova V., Spure Zh., Naidenov M., Zhizhin K., Malinina E., Chernyavsky A., Lukyanets E., Solntsev K., Kuznetsov N., Borisov G. in: *Frontiers in Neutron Capture Therapy* (M. F. Hawthorne, K. Shelly and R. J. Wiersema, Eds), Vol. 2, p. 1027. Kluwer Academic/Plenum Publ., New York 2001.
199. Agafonov A. V., Butman L. A., Solntsev K. A., Vinokurov A. A., Zhukova N. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1983**, *27*, 35.
200. Nachtigal C., Haeckel O., Preetz W.: *Z. Anorg. Allg. Chem.* **1997**, *623*, 1385.
201. Mitchell G. F., Welch A. J.: *Acta Crystallogr., Sect. C: Cryst. Struct. Commun.* **1986**, *42*, 101.
202. Miller H. C., Hertler W. R., Muettterties E. L., Knoth W. H., Miller N. E.: *Inorg. Chem.* **1965**, *4*, 1216.
203. Strauss S. H.: Presented at *VIIIth Boron Americas Conf. BORON AMERICAS, Furnace Creek 2002*.
204. Hertler W. R.: *Inorg. Chem.* **1964**, *3*, 1195.
205. Lisovskii M. V., Zhizhin K. Yu., Kuznetsov N. T.: Unpublished results.
206. Sivaev I. B., Bruskin A. B., Nesterov V. V., Antipin M. Yu., Bregadze V. I., Sjöberg S.: *Inorg. Chem.* **1999**, *38*, 5887.
207. Bregadze V. I., Sivaev I. B., Bruskin A. B., Sjöberg S., Nesterov V. V., Antipin M. Yu. in: *Contemporary Boron Chemistry* (M. Davidson, A. K. Hughes, T. B. Marder and K. Wade, Eds), p. 162. Royal Chem. Soc., Cambridge 2000.
208. Sivaev I. B., Bruskin A. B., Nesterov V. V., Antipin M. Yu., Bregadze V. I., Sjöberg S. in: *Frontiers in Neutron Capture Therapy* (M. F. Hawthorne, K. Shelly and R. J. Wiersema, Eds), Vol. 2, p. 779. Kluwer Academic/Plenum Publ., New York 2001.
209. Koch T., Preetz W.: *Z. Naturforsch., B: Chem. Sci.* **1997**, *52*, 939.
210. Koch T., Preetz W.: *Z. Naturforsch., B: Chem. Sci.* **1997**, *52*, 1165.
211. Zhang G., Jiang F., Zhang L. in: *New Frontiers Rare Earth Sci. Appl., Proc. Int. Conf. Rare Earth Dev. Appl.* (G. Xu and J. Xiao, Eds), Vol. 1, p. 187. Sci. Press, Beijing 1985.

212. Zhang G., Jiang F., Zhang Z. W.: *Huaxue* **1987**, 3(1), 51; *Chem. Abstr.* **1987**, 107, 210936.
213. Hu P., Zhang L., Wu H., Wang F.: *Gaodeng Xuexiao Huaxue Xuebao* **1991**, 12, 864; *Chem. Abstr.* **1992**, 117, 19121.
214. Norman A. H., Kaczmarczyk A.: *Inorg. Chem.* **1974**, 13, 2316.
215. Zhizhin K. Yu., Votnova N. A., Goeva L. V., Kuznetsov N. T.: *Russ. J. Coord. Chem.* **2001**, 27, 625.
216. Jasper S. A., Jones R. B., Mattern J., Huffman J. C., Todd L. J.: *Inorg. Chem.* **1994**, 33, 5620.
217. Semioshkin A. A., Petrovskii P. V., Sivaev I. B., Balandina E. G., Bregadze V. I.: *Russ. Chem. Bull.* **1996**, 45, 683.
218. Semioshkin A., Brellochs B.: Presented at VIIIth Int. Meet. Boron Chem. IMEBORON, Knoxville 1993.
219. Bechtold R., Kaczmarczyk A.: *J. Am. Chem. Soc.* **1974**, 96, 5953.
220. Peymann T., Knobler C. B., Hawthorne M. F.: *Inorg. Chem.* **2000**, 39, 1163.
221. Peymann T., Shelly K., Hawthorne M. F. in: *Frontiers in Neutron Capture Therapy* (M. F. Hawthorne, K. Shelly and R. J. Wiersema, Eds), Vol. 2, p. 775. Kluwer Academic/Plenum Publ., New York 2001.
222. Antsyshkina A. S., Sadikov G. G., Gorobinskii L. V., Chernyavskii A. S., Solntsev K. A., Sergienko V. S., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **2001**, 46, 1323.
223. Krause U., Preetz W.: *Z. Anorg. Allg. Chem.* **1995**, 621, 516.
224. Haeckel O., Preetz W.: *Z. Anorg. Allg. Chem.* **1998**, 624, 1089.
225. Peymann T., Herzog A., Knobler C. B., Hawthorne M. F.: *Angew. Chem., Int. Ed.* **1999**, 38, 1062.
226. Peymann T., Knobler C. B., Khan S. I., Hawthorne M. F.: *J. Am. Chem. Soc.* **2001**, 123, 2182.
227. Peymann T., Lork E., Gabel D.: *Inorg. Chem.* **1996**, 35, 1355.
228. Sivaev I. B., Sjöberg S., Bregadze V. I., Gabel D.: *Tetrahedron Lett.* **1999**, 40, 3451.
229. Wang F., Wang X.: *He Huaxue Yu Fangshe Huaxue* **1999**, 21, 153; *Chem. Abstr.* **2000**, 133, 131870.
230. Preetz W., Haeckel O.: *Z. Anorg. Allg. Chem.* **1995**, 621, 1283.
231. Brellochs B., Semioshkin A.: *Russ. Chem. Bull.* **1995**, 44, 406.
232. Peymann T., Knobler C. B., Khan S. I., Hawthorne M. F.: *Angew. Chem., Int. Ed.* **2001**, 40, 1664.
233. Sivaev I. B., Semioshkin A. A., Brellochs B., Sjöberg S., Bregadze V. I.: *Polyhedron* **2000**, 19, 627.
234. Sivaev I. B., Bregadze V. I., Sjöberg S. in: *Contemporary Boron Chemistry* (M. Davidson, A. K. Hughes, T. B. Marder and K. Wade, Eds), p. 135. Royal Chem. Soc., Cambridge 2000.
235. a) Bernard R., Cornu D., Grüner B., Dozol J.-F., Miele P., Bonnetot B.: Presented at IInd Eur. Symp. Boron Chem. EUROBORON, Dinard 2001; b) Bernard R., Cornu D., Grüner B., Dozol J.-F., Miele P., Bonnetot B.: *J. Organomet. Chem.*, in press.
236. Peymann T., Kück K., Gabel D.: *Inorg. Chem.* **1997**, 36, 5138.
237. Zhizhin K. Yu., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **2002**, 47, 346.
238. Gorobinskii L. V., Chernyavskii A. S., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Coord. Chem.* **2001**, 27, 147.
239. Maderna A., Knobler C. B., Hawthorne M. F.: *Angew. Chem., Int. Ed.* **2001**, 40, 1662.

240. Thomas J., Hawthorne M. F.: *Chem. Commun.* **2001**, 1884.
241. Bechtold R. A., Kaczmarczyk A., Messer R. J.: *J. Med. Chem.* **1975**, 18, 371.
242. Maderna A., Huertas R., Li T. J., Grell J., Orf J., Bross B., Hawthorne M. F.: Presented at *VIIIth Boron Americas Conf. BORON AMERICAS, Furnace Creek 2002*.
243. Tolpin E. I., Wellum G. R., Berley S. A.: *Inorg. Chem.* **1978**, 17, 2867.
244. Komura M., Aono K., Nagasawa K., Sumimoto S.: *Chem. Express* **1987**, 2, 173.
245. Brattsev V. A., Sagitullin O. R., Spryshkova R. A., Naidenov M. G.: Presented at *IInd Int. Symp. CMEA States on Stable Isotopes, Tbilisi 1989*.
246. Brattsev V. A., Morris J. H. in: *Advances in Neutron Capture Therapy* (B. Larsson, J. Crawford and R. Weinreich, Eds), Vol. 2, p. 51. Elsevier Science B. V., Amsterdam 1997.
247. Shiro M., Aono K., Watanabe H.: *Chem. Ind.* **1970**, 564.
248. Gabel D., Moller D., Harfst S., Rösler J., Ketz H.: *Inorg. Chem.* **1993**, 32, 2276.
249. Broomhead J. A., Lynch M. J.: *Inorg. Chim. Acta* **1995**, 240, 19.
250. Yeager L. J., Saeki F., Shelly K., Hawthorne M. F., Garrell R. L.: *J. Am. Chem. Soc.* **1998**, 120, 9961.
251. Schmid G., Pugin R., Meyer-Zaika W., Simon U.: *Eur. J. Inorg. Chem.* **1999**, 2051.
252. Wellum G. R., Tolpin E. I., Soloway A. H., Kaczmarczyk A.: *Inorg. Chem.* **1977**, 16, 2120.
253. Yoshizaki T., Ikeuchi I., Nagasawa K. in: *Neutron Capture Therapy, Proc. 2nd Int. Symp.* (H. Hatanaka, Ed.), p. 394. Nishimura, Niigata 1986.
254. Nagasawa K., Ikeuchi Y., Nakagawa Y.: *J. Organomet. Chem.* **1990**, 391, 139.
255. Ikeuchi I., Amano T.: *J. Chromatogr.* **1987**, 396, 273.
256. Ikeuchi I., Amano T.: *Anal. Sci.* **1987**, 3, 561.
257. Miura M., Micca P. L., Heinrichs J. C., Slatkin D. N. in: *Advances in Neutron Capture Therapy* (A. H. Soloway, Ed.), p. 339. Plenum Press, New York 1993.
258. Ikeuchi I., Aono T.: *Bunseki Kagaku* **1988**, 37, 211.
259. Stopka P., Štrouf O.: *Collect. Czech. Chem. Commun.* **1991**, 56, 657.
260. Štrouf O., Stopka P., Velická J., Bednářová S., Krupička J., Jelen F., Paleček E., Šerák L. in: *Progress in Neutron Capture Therapy for Cancer* (B. J. Allen, Ed.), p. 335. Plenum Press, New York 1992.
261. Brattsev V. A., Storozhenko P. A., Danilova G. N.: *IInd Eur. Symp. Boron Chem. EUROBORON*, Book of Abstracts, p. O6. Université de Rennes, Dinard 2001.
262. Alam F., Soloway A. H., McGuire J. E., Barth R. F., Carey W. E., Adams D.: *J. Med. Chem.* **1985**, 28, 522.
263. Kultyshev R. G., Li S., Shore S. G.: *Inorg. Chem.* **2000**, 39, 6094.
264. Harfst S., Moller D., Ketz H., Rösler J., Gabel D.: *J. Chromatogr., A* **1994**, 678, 41.
265. Gabel D., Harfst S., Moller D., Ketz H., Peymann T., Rösler J.: *Current Topics in the Chemistry of Boron*, p. 161. Royal Chem. Soc., Cambridge 1994.
266. Peymann T., Preusse D., Gabel D. in: *Advances in Neutron Capture Therapy* (B. Larsson, J. Crawford and R. Weinreich, Eds), Vol. 2, p. 35. Elsevier Science B. V., Amsterdam 1997.
267. Nagasawa K., Narisada M.: *Tetrahedron Lett.* **1990**, 31, 4029.
268. Swenson D. H., Laster B. H., Metzger R. L.: *J. Med. Chem.* **1996**, 39, 1540.
269. Berger M., Schmidtchen F. P.: *J. Am. Chem. Soc.* **1996**, 118, 8947.
270. Berger M., Schmidtchen F. P.: *Angew. Chem., Int. Ed.* **1998**, 37, 2694.
271. Berger M., Schmidtchen F. P.: *J. Am. Chem. Soc.* **1999**, 121, 9986.
272. Perleberg O., Gabel D. in: *Advances in Neutron Capture Therapy* (B. Larsson, J. Crawford and R. Weinreich, Eds), Vol. 2, p. 119. Elsevier Science B. V., Amsterdam 1997.

273. Gula M., Perleberg O., Gabel D. in: *Contemporary Boron Chemistry* (M. Davidson, A. K. Hughes, T. B. Marder and K. Wade, Eds), p. 115. Royal Chem. Soc., Cambridge 2000.
274. Wright J., Kaczmarczyk A.: *Inorg. Chem.* **1973**, *12*, 1453.
275. Sneath R. L., Soloway A. H., Dey A. S.: *J. Med. Chem.* **1974**, *17*, 796.
276. Hamilton E. J. M., Jordan G. T., IV, Meyers E. A., Shore S. G.: *Inorg. Chem.* **1996**, *35*, 5335.
277. Kultyshev R. G., Liu J., Meyers E. A., Shore S. G.: *Inorg. Chem.* **1999**, *38*, 4913.
278. Kultyshev R. G., Liu J., Meyers E. A., Shore S. G.: *Inorg. Chem.* **2000**, *39*, 3333.
279. Kultyshev R., Liu J., Shore S. G. in: *Contemporary Boron Chemistry* (M. Davidson, A. K. Hughes, T. B. Marder and K. Wade, Eds), p. 167. Royal Chem. Soc., Cambridge 2000.
280. Kultyshev R. G., Liu J., Liu Sh., Tjarks W., Soloway A. H., Shore S. G.: *J. Am. Chem. Soc.* **2002**, *124*, 2614.
281. Lu Y.-X., Ding H.-X., Lu H.-M.: *Acta Chim. Sin.* **1990**, *48*, 820.
282. Sano T.: *Bioconjugate Chem.* **1999**, *10*, 905.
283. Srebny H.-G., Preetz W.: *Z. Anorg. Allg. Chem.* **1984**, *513*, 7.
284. Sivaev I. B., Katser S. B., Solntsev K. A., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **1995**, *40*, 779.
285. Morris J. H., Brattsev V. A., Gaines D. F. in: *Advances in Boron Chemistry* (W. Siebert, Ed.), p. 434. Royal Chem. Soc., Cambridge 1997.
286. Gorobinskii L. V., Antsyshkina A. S., Sadikov G. G., Chernyavskii A. S., Solntsev K. A., Sergienko V. S., Kuznetsov N. T.: *Russ. J. Inorg. Chem.* **2001**, *46*, 691.
287. Nachtigal C., Steuer B., Preetz W.: *Chem. Ber.* **1996**, *129*, 1531.
288. Kper J., Conrad O., Krebs B.: *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 1903.
289. Lindemann A., Kuchinke J., Krebs B.: *Z. Anorg. Allg. Chem.* **1999**, *625*, 1165.
290. Hammerschmidt A., Lindemann A., Köster C., Krebs B.: *Z. Anorg. Allg. Chem.* **2001**, *627*, 2121.
291. Brattsev V. A., Sagitullin O. R.: *J. Gen. Chem. U.S.S.R.* **1988**, *58*, 820.
292. a) Yakushev A. B., Sivaev I. B., Solntsev K. A., Kuznetsov N. T.: *Koord. Khim.* **1990**, *16*, 594; b) Yakushev A. B., Sivaev I. B., Solntsev K. A., Kuznetsov N. T.: *Koord. Khim.* **1990**, *16*, 867.
293. Grushin V. V., Bregadze V. I., Kalinin V. N.: *Organomet. Chem. Rev.* **1988**, *20*, 1.
294. Schroeder M. A.: *J. Popul. Power* **1998**, *14*, 981.
295. Johnson S., Barr L. H., Smith B. E.: PCT Int. Appl. WO 99 16,731; *Chem. Abstr.* **1999**, *130*, 239635.
296. Shibata A., Miyake A., Ogawa T.: *Kayaku Gakkaishi* **2000**, *61(2)*, 85; *Chem. Abstr.* **2000**, *133*, 137514.
297. Johnson J. W., Whittingham M. S.: *J. Electrochem. Soc.* **1980**, *127*, 1653.
298. Johnson J. W., Thompson A. H.: *J. Electrochem. Soc.* **1981**, *128*, 932.
299. Armand M.: PCT Int. Appl. WO 83 03,322; *Chem. Abstr.* **1984**, *100*, 10063.
300. Ubukawa S., Nakatani N.: Jpn. Kokai Tokkyo Koho JP 61,165,957 [86,165,957]; *Chem. Abstr.* **1986**, *105*, 211922.
301. Kaszynski P., Douglass A. G.: *J. Organomet. Chem.* **1999**, *581*, 28.
302. Fibbioli M., Berger M., Schmidtchen F. P., Pretsch E.: *Anal. Chem.* **2000**, *72*, 156.
303. Saldin V. I., Tsvetnikov A. K., Buzhik V. M.: RU 2 123 474; *Chem. Abstr.* **2000**, *133*, 60936.
304. Drake C. A.: U.S. 5 981 417; *Chem. Abstr.* **2000**, *132*, 339340.
305. Sivaev I. B., Bregadze V. I., Kuznetsov N. T.: *Russ. Chem. Bull.*, in press.

306. Barth R. F., Soloway A. H., Fairchild R. G., Brugger R. M.: *Cancer* **1992**, 70, 2995.
307. Carlsson J., Sjöberg S., Larsson B.: *Acta Oncol.* **1992**, 31, 803.
308. Hawthorne M. F.: *Angew. Chem., Int. Ed. Engl.* **1993**, 32, 950.
309. Soloway A. H., Tjarks W., Barnum B. A., Rong F.-G., Barth R. F., Codogni I. M., Wilson J. G.: *Chem. Rev. (Washington, D. C.)* **1998**, 98, 1515.
310. Johnson L. S., Yanch J. C., Shortkroff S., Sledge C. B. in: *Cancer Neutron Capture Therapy* (Y. Mishima, Ed.), p. 183. Plenum, New York 1996.
311. Wilbur D. S., Hamlin D. K., Buhler K. R., Srivastava R. R., Strey J. E., Daniel J., Vessela R. J.: *Q. J. Nucl. Med.* **1995**, 39, 51.
312. Tolmachev V., Lundqvist H., Sivaev I., Orlova A., Sjöberg S., Olsson P., Gedda L.: *J. Labelled Compd. Radiopharm.* **1997**, 40, 122.
313. Tolmachev V., Lundqvist H., Carlsson J., Sivaev I., Orlova A., Sundin A.: *J. Labelled Compd. Radiopharm.* **1997**, 40, 125.
314. Tolmachev V., Koziorowski J., Sivaev I., Lundqvist H., Carlsson J., Orlova A., Gedda L., Olsson P., Sjöberg S., Sundin A.: *Bioconjugate Chem.* **1999**, 10, 338.
315. Orlova A., Lebeda O., Tolmachev V., Sjöberg S., Carlsson J., Lundquist H.: *J. Labelled Compd. Radiopharm.* **2000**, 43, 251.
316. Orlova A., Lebeda O., Tolmachev V., Sjöberg S., Carlsson J., Lundquist H. in: *Contemporary Boron Chemistry* (M. Davidson, A. K. Hughes, T. B. Marder and K. Wade, Eds), p. 144. Royal Chem. Soc., Cambridge 2000.
317. Tolmachev V., Bruskin A., Sivaev I., Lundqvist H., Sjöberg S.: *Radiochim. Acta* **2002**, 90, 229.
318. Tolmachev V., Sivaev I., Bruskin A., Sjöberg S.: *Eur. J. Nucl. Med.* **2000**, 27, 1062.
319. Bruskin A., Sivaev I., Persson M., Lundqvist H., Sjöberg S., Tolmachev V.: *Bioconjugate Chem.*, in press.
320. Grainger R. G.: *Br. J. Radiol.* **1982**, 55(649), 1.
321. POV Reports: *The Diagnostic Imaging Marketplace in the U.S.* POV Inc., Cedar Grove (NJ) 1998.
322. Wilbur D. S.: PCT Int. Appl. WO 95 05,202; *Chem. Abstr.* **1995**, 123, 199134.
323. Meyer D., Spielvogel B. F.: PCT Int. Appl. WO 93 08,122; *Chem. Abstr.* **1993**, 119, 90286.
324. Hall I. H., Brotherton R. J.: U.S. 4,672,060 (1987); *Chem. Abstr.* **1987**, 107, 70812.
325. Hall I. H., Elkins A., Powell W. J., Karthikeyan S., Sood A., Spielvogel B. F.: *Anticancer Res.* **1998**, 18, 2617.